<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">BMC Infect. Dis</journal-id><journal-title-group><journal-title>BMC Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">1471-2334</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29258448</article-id><article-id pub-id-type="pmc">5738206</article-id><article-id pub-id-type="publisher-id">2876</article-id><article-id pub-id-type="doi">10.1186/s12879-017-2876-9</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Factors contributing to anaemia after uncomplicated falciparum malaria in under five year-old Nigerian children ten years following adoption of artemisinin-based combination therapies as first-line antimalarials</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Sowunmi</surname><given-names>Akintunde</given-names></name><address><phone>+2348023359390</phone><email>akinsowunmi@hotmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff20">20</xref></contrib><contrib contrib-type="author"><name><surname>Fatunmbi</surname><given-names>Bayo</given-names></name><address><email>fatunmbib@who.int</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Akano</surname><given-names>Kazeem</given-names></name><address><email>heycarnow@yahoo.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Wewe</surname><given-names>Olubunmi A.</given-names></name><address><email>olubunmiwewe@gmail.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Agomo</surname><given-names>Chimere</given-names></name><address><email>agomoco@hotmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Finomo</surname><given-names>Finomo</given-names></name><address><email>fobfinomo@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Ebenebe</surname><given-names>Joy</given-names></name><address><email>joycebenebe@yahoo.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Jiya</surname><given-names>Nma</given-names></name><address><email>nmajiya2013@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Ambe</surname><given-names>Jose</given-names></name><address><email>jpambe1@yahoo.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Wammanda</surname><given-names>Robinson</given-names></name><address><email>wammanda@yahoo.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Ntadom</surname><given-names>Godwin</given-names></name><address><email>ntadomg@yahoo.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Mokuolu</surname><given-names>Olugbenga</given-names></name><address><email>oamokuolu@yahoo.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Emechebe</surname><given-names>George</given-names></name><address><email>nnabuike20g@yahoo.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Ezeigwe</surname><given-names>Nnenna</given-names></name><address><email>drninaezeigwe@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ayede</surname><given-names>Adejumoke I.</given-names></name><address><email>idayede@yahoo.co.uk</email></address><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>Adewoye</surname><given-names>Elsie O.</given-names></name><address><email>elolade@yahoo.com</email></address><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Gbotosho</surname><given-names>Grace O.</given-names></name><address><email>solagbotosho@yahoo.co.uk</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author"><name><surname>Folarin</surname><given-names>Onikepe A.</given-names></name><address><email>folarino@run.edu.ng</email></address><xref ref-type="aff" rid="Aff16">16</xref></contrib><contrib contrib-type="author"><name><surname>Happi</surname><given-names>Christian T.</given-names></name><address><email>happic@run.edu.ng</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff16">16</xref></contrib><contrib contrib-type="author"><name><surname>Oguche</surname><given-names>Stephen</given-names></name><address><email>soguche2001@yahoo.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff17">17</xref></contrib><contrib contrib-type="author"><name><surname>Oyibo</surname><given-names>Wellington A.</given-names></name><address><email>wellao@yahoo.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff18">18</xref></contrib><contrib contrib-type="author"><name><surname>Useh</surname><given-names>Francis</given-names></name><address><email>francisuseh@yahoo.co.uk</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff19">19</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.434433.7</institution-id><institution>Antimalarial Therapeutic Efficacy Monitoring Group, National Malaria Elimination Programme, The Federal Ministry of Health, </institution></institution-wrap>Abuja, Nigeria </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1794 5983</institution-id><institution-id institution-id-type="GRID">grid.9582.6</institution-id><institution>Department of Pharmacology and Therapeutics, </institution><institution>University of Ibadan, </institution></institution-wrap>Ibadan, Nigeria </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1794 5983</institution-id><institution-id institution-id-type="GRID">grid.9582.6</institution-id><institution>Institute for Medical Research and Training, </institution><institution>University of Ibadan, </institution></institution-wrap>Ibadan, Nigeria </aff><aff id="Aff4"><label>4</label>World Health Organization, Country Office, Kampala, Uganda </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1803 1817</institution-id><institution-id institution-id-type="GRID">grid.411782.9</institution-id><institution>Department of Medical Laboratory Science, </institution><institution>University of Lagos, </institution></institution-wrap>Lagos, Nigeria </aff><aff id="Aff6"><label>6</label>Department of Paediatrics, Federal Medical Centre, Yenagoa, Nigeria </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0117 5863</institution-id><institution-id institution-id-type="GRID">grid.412207.2</institution-id><institution>Department of Paediatrics, Nnamdi Azikiwe University, </institution></institution-wrap>Awka, Nigeria </aff><aff id="Aff8"><label>8</label>Department of Paediatrics, Uthman Dan Fodio University, Sokoto, Nigeria </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9001 9645</institution-id><institution-id institution-id-type="GRID">grid.413017.0</institution-id><institution>Department of Paediatrics, </institution><institution>University of Maiduguri, </institution></institution-wrap>Maiduguri, Nigeria </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1937 1493</institution-id><institution-id institution-id-type="GRID">grid.411225.1</institution-id><institution>Department of Paediatrics, </institution><institution>Ahmadu Bello University, </institution></institution-wrap>Zaria, Nigeria </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0625 9425</institution-id><institution-id institution-id-type="GRID">grid.412974.d</institution-id><institution>Department of Paediatrics, </institution><institution>University of Ilorin, </institution></institution-wrap>Ilorin, Nigeria </aff><aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="GRID">grid.411541.4</institution-id><institution>Department of Paediatrics, </institution><institution>Imo State University Teaching Hospital, </institution></institution-wrap>Orlu, Nigeria </aff><aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1794 5983</institution-id><institution-id institution-id-type="GRID">grid.9582.6</institution-id><institution>Department of Paediatrics, </institution><institution>University of Ibadan, </institution></institution-wrap>Ibadan, Nigeria </aff><aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1794 5983</institution-id><institution-id institution-id-type="GRID">grid.9582.6</institution-id><institution>Department of Physiology, </institution><institution>University of Ibadan, </institution></institution-wrap>Ibadan, Nigeria </aff><aff id="Aff15"><label>15</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1794 5983</institution-id><institution-id institution-id-type="GRID">grid.9582.6</institution-id><institution>Department of Pharmacology and Toxicology, </institution><institution>University of Ibadan, </institution></institution-wrap>Ibadan, Nigeria </aff><aff id="Aff16"><label>16</label>Department of Biological Sciences and African Centre of Excellence for Genomics of Infectious Diseases (ACEGID), Redeemer University, Ede, Nigeria </aff><aff id="Aff17"><label>17</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 8510 4538</institution-id><institution-id institution-id-type="GRID">grid.412989.f</institution-id><institution>Department of Paediatrics, </institution><institution>University of Jos, </institution></institution-wrap>Jos, Nigeria </aff><aff id="Aff18"><label>18</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1803 1817</institution-id><institution-id institution-id-type="GRID">grid.411782.9</institution-id><institution>Department of Medical Microbiology and Parasitology, </institution><institution>University of Lagos, </institution></institution-wrap>Lagos, Nigeria </aff><aff id="Aff19"><label>19</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0291 6387</institution-id><institution-id institution-id-type="GRID">grid.413097.8</institution-id><institution>Department of Medical Laboratory Science, </institution><institution>University of Calabar, </institution></institution-wrap>Calabar, Nigeria </aff><aff id="Aff20"><label>20</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1764 5403</institution-id><institution-id institution-id-type="GRID">grid.412438.8</institution-id><institution>Department of Clinical Pharmacology, University College Hospital, </institution></institution-wrap>Ibadan, Nigeria </aff></contrib-group><pub-date pub-type="epub"><day>19</day><month>12</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>19</day><month>12</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>17</volume><elocation-id>781</elocation-id><history><date date-type="received"><day>4</day><month>7</month><year>2017</year></date><date date-type="accepted"><day>30</day><month>11</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Artemisinin-based combination therapies (ACTs) have remained efficacious treatments of acute falciparum malaria in many endemic areas but there is little evaluation of factors contributing to the anaemia of acute falciparum malaria following long term adoption of ACTs as first-line antimalarials in African children.</p></sec><sec><title>Methods</title><p id="Par2">Malarious &#x0003c;5&#x000a0;year-olds randomized to artemether-lumefantrine, artesunate-amodiaquine or dihydroartemisinin-piperaquine treatments were followed up clinically for 6&#x000a0;weeks. Anaemia was defined as haematocrit &#x0003c;30%; Malaria-attributable fall in haematocrit (MAFH) as the difference between haematocrit 28&#x02013;42&#x000a0;days post- and pre-treatment; Total MAFH (TMAFH) as the difference between days 28&#x02013;42 haematocrit and the lowest haematocrit recorded in the first week post-treatment initiation; Drug-attributable fall in haematocrit (DAFH) as the difference between MAFH and TMAFH; Early appearing anaemia (EAA) as haematocrit &#x0003c;30% occurring within 1&#x000a0;week in children with normal haematocrit pre-treatment. Predictors of anaemia pre-treatment, EAA, MAFH or DAFH &#x0003e;4% were evaluated by stepwise multiple logistic regression models. Survival analysis and kinetics of DAFH were evaluated by Kaplan-Meier estimator and non-compartment model, respectively.</p></sec><sec><title>Results</title><p id="Par3">Pre-treatment, 355 of 959 children were anaemic. Duration of illness &#x0003e;2&#x000a0;days and parasitaemia &#x02264;10,000&#x000a0;&#x003bc;L<sup>&#x02212;1</sup> were independent predictors of anaemia pre-treatment. EAA occurred in 301 of 604 children. Predictors of EAA were age&#x02009;&#x02264;&#x02009;15&#x000a0;months, history of fever pre-treatment and enrolment haematocrit &#x02264;35%. The probabilities of progression from normal haematocrit to EAA were similar for all treatments. MAFH &#x0003e;4% occurred in 446 of 694 children; its predictors were anaemia pre-treatment, enrolment parasitaemia &#x02264;50,000&#x000a0;&#x003bc;L<sup>&#x02212;1</sup>, parasitaemia one day post-treatment initiation and gametocytaemia. DAFH &#x0003e;4% occurred in 334 of 719 children; its predictors were history of fever pre-and fever 1&#x000a0;day post-treatment initiation, haematocrit &#x02265;37%, and parasitaemia &#x0003e;100,000&#x000a0;&#x003bc;L<sup>&#x02212;1</sup>. In 432 children, declines in DAFH deficits were monoexponential with overall estimated half-time of 2.2d (95% CI 1.9&#x02013;2.6). Area under curve of deficits in DAFH versus time and estimated half-time were significantly higher in non-anaemic children indicating greater loss of haematocrit in these children.</p></sec><sec><title>Conclusion</title><p id="Par4">After ten years of adoption of ACTs, anaemia is common pre-and early post-treatment, falls in haematocrit attributable to a single infection is high, and DAFH &#x0003e;4% is common and significantly lower in anaemic compared to non-anaemic Nigerian children.</p></sec><sec><title>Trial registration</title><p id="Par5">Pan African Clinical Trial Registry (PACTR) [<ext-link ext-link-type="uri" xlink:href="http://www.pactr.org">PACTR201709002064150, 1 March 2017</ext-link>].</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd><italic>Plasmodium falciparum</italic> malaria-associated anaemia</kwd><kwd>Artemisinin-based combination treatments</kwd><kwd>Children</kwd><kwd>Nigeria</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par30">Artemisinin-based combination therapies (ACTs) have been adopted as first-line treatments of uncomplicated <italic>Plasmodium falciparum</italic> malaria by over 80 countries [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>]. In many of these countries particularly those in southeast Asia, the period of adoption as first-line treatments has exceeded 10&#x000a0;years [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. In Nigeria, artemether-lumefantrine (AL) and artesunate-amodiaquine (AA) were adopted as first-line treatments in 2005 [<xref ref-type="bibr" rid="CR6">6</xref>].</p><p id="Par31">Anaemia, a consequence of treated and untreated falciparum malaria, is common before, during or after treatment in up to 40% of African children [<xref ref-type="bibr" rid="CR7">7</xref>&#x02013;<xref ref-type="bibr" rid="CR9">9</xref>]. It is a major public health problem, and in anaemic patients, has been attributed to repeated infections within a short time frame, bone marrow dyserythropoiesis and increased splenic clearance of infected and non-infected erythrocytes [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR13">13</xref>]. Anaemia can also occur in African children with apparently asymptomatic infections [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>].</p><p id="Par32">Despite adoption as first-line treatments in many countries for over a decade, there is little evaluation of the predictors of anaemia before, during or in the 1&#x000a0;week following initiation of treatment in malarious children. In malarious patients, the effects of infections and the drugs used to treat the infections can be evaluated using the following indices: malaria-attributable fall in haematocrit (MAFH), total malaria-attributable fall in haematocrit (TMAFH) [<xref ref-type="bibr" rid="CR10">10</xref>], or drug-attributable fall in haematocrit (DAFH) [<xref ref-type="bibr" rid="CR16">16</xref>]. Such evaluations are urgently needed as they can provide useful leads in the diagnosis and management of the anaemia following ACTs, and the extent to which adoption of ACTs as first-line antimalarials has modified the burden of the anaemia associated with malaria infections. From the clinical point of view, worsening of haematocrit levels or falls in haematocrit following ACTs of uncomplicated falciparum malaria in young African children, until proven otherwise, can be considered an adverse event attributable to the drug(s) used [<xref ref-type="bibr" rid="CR17">17</xref>] &#x02013; drug attributable falls in haematocrit [<xref ref-type="bibr" rid="CR16">16</xref>]. However, DAFH can be attributed to interaction between the drug, the infection and the host.</p><p id="Par33">For the reasons indicated above, the aims of present study were: using pre-determined cut-offs (haematocrit &#x0003c;30%, MAFH or DAFH &#x0003e;4%), to evaluate the predictors of the following: anaemia at presentation, progression from normal haematocrit at presentation to anaemia within 1&#x000a0;week of starting treatment (early-appearing anaemia [EAA]), and MAFH or DAFH &#x0003e;4% in a group of under 5&#x000a0;year old malarious children who were treated with AL, AA or dihydroartemisinin-piperaquine (DHP), during an open labelled therapeutic efficacy study. An additional aim was to evaluate the kinetics of the disposition of DAFH in anaemic and non-anaemic children following initiation of treatment.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study locations</title><p id="Par34">The study took place between June 2014 and September 2015. It was part of a programme to monitor antimalarial therapeutic efficacy at eight sentinel sites located in six geographical areas of Nigeria namely, Ogbia, Neni, Ogwa, Numan, Ilorin, Kura, Bodinga and Ibadan in Bayelsa, Anambra, Imo, Adamawa, Kwara, Kano, Sokoto and Oyo States, respectively. In virtually all study locations, malaria is hyperendemic and transmission occurs all year round; however, it is more intense during the rainy season from April to October. The details of the therapeutic efficacy study will be described elsewhere. The dataset presented here have not been previously published elsewhere.</p></sec><sec id="Sec4"><title>Study procedures</title><p id="Par35">Standardized procedures and protocol were used at all sentinel sites. Briefly, patients were eligible to participate in the study if they were: aged 6&#x02013;59&#x000a0;months, had symptoms compatible with acute uncomplicated malaria and <italic>P. falciparum</italic> mono-infections between 2000 and 200,000&#x000a0;&#x003bc;L<sup>&#x02212;1</sup> of blood, no history of antimalarial drug ingestion in the two weeks preceding enrolment, had no evidence of severe malaria [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>] and parents or guardians gave written informed consent.</p><p id="Par36">Enrolled patients were randomized to AL, AA or DHP treatments for 3&#x000a0;days (day 0&#x02013;2) as previously described [<xref ref-type="bibr" rid="CR20">20</xref>]. The day of presentation (day of starting treatment) was regarded as day 0. Thick and thin blood films were obtained from each child as soon as they came to the clinic and the slides were carefully labelled with the patients&#x02019; codes and air-dried before being Giemsa-stained. Follow-up with clinical and parasitological evaluation was done daily on days 1&#x02013;3 and 7, and thereafter, weekly for additional 5&#x000a0;weeks. Parasitaemia, asexual or sexual, in thick films was estimated by counting asexual and sexual parasites relative to 500 leukocytes, or 500 asexual or sexual forms whichever occurred first. From this figure, the parasite density was calculated assuming a leukocyte count of 6000&#x000a0;&#x003bc;L<sup>&#x02212;1</sup> of blood [<xref ref-type="bibr" rid="CR21">21</xref>]. A slide was considered asexual parasite negative if no asexual parasite was detected after examination of 200 microscope fields. Parasite reduction ratio was defined as previously described [<xref ref-type="bibr" rid="CR22">22</xref>].</p></sec><sec id="Sec5"><title>Haematological evaluation</title><p id="Par37">Capillary blood obtained from a finger prick was collected before treatment and during follow-up<underline>,</underline> and was used to measure haematocrit using a microhaematocrit tube and microcentrifuge (Hawksley, Lancing, UK). Anaemia was defined as a haematocrit &#x0003c;30% and was further classified as mild, moderate or severe if haematocrit was 21&#x02013;29%, 15&#x02013;20% or &#x0003c;15%, respectively [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR10">10</xref>].</p></sec><sec id="Sec6"><title>Definition of haematological parameters evaluated</title><p id="Par38">The following parameters described by Price et al. [<xref ref-type="bibr" rid="CR10">10</xref>] and modified by Sowunmi et al. [<xref ref-type="bibr" rid="CR16">16</xref>] were used for evaluation (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>):<list list-type="simple"><list-item><label>(i)</label><p id="Par39">
<italic>Malaria-attributable fall in haematocrit (MAFH)</italic> before treatment was defined as the difference between the patient&#x02019;s maximum haematocrit value measured on days 28&#x02013;42 and that on day 0 (pre-treatment).</p></list-item><list-item><label>(ii)</label><p id="Par40">
<italic>Total malaria-attributable fall in haematocrit (TMAFH)</italic> was defined as the difference between the patient&#x02019;s maximum haematocrit on days 28&#x02013;42 and lowest haematocrit value recorded in the first week post-treatment initiation.</p></list-item><list-item><label>(iii)</label><p id="Par41">
<italic>Drug-attributable falls in haematocrit (DAFH)</italic> was defined as the difference between MAFH and TMAFH, or as the difference between pre-treatment haematocrit and the lowest haematocrit recorded in the first week post-treatment initiation.</p></list-item><list-item><label>(iv)</label><p id="Par42">
<italic>Early-appearing anaemia (EAA)</italic> was defined as haematocrit &#x0003c;30% occurring within 1&#x000a0;week in patients who were non-anaemic pre-treatment.</p></list-item><list-item><label>(v)</label><p id="Par43">
<italic>Anaemia recovery time:</italic> Anaemia recovery time (in anaemic children pre-treatment) was defined as time elapsing from initiation of treatment to attainment of haematocrit value &#x02265;30%. In non-anaemic children (pre-treatment) who subsequently progressed to anaemia following initiation of treatment (early-appearing anaemia), anaemia recovery time was defined as the time from the appearance of (onset of anaemia), to recovery from anaemia (until haematocrit rose to &#x02265;30%).</p></list-item></list>
<fig id="Fig1"><label>Fig. 1</label><caption><p>Parameters used for estimation of malaria-related falls in haematocrit (adapted from Price et al. [<xref ref-type="bibr" rid="CR10">10</xref>] and Sowunmi et al. [<xref ref-type="bibr" rid="CR16">16</xref>]</p></caption><graphic xlink:href="12879_2017_2876_Fig1_HTML" id="MO1"/></fig>
</p></sec><sec id="Sec7"><title>Kinetics of the disposition of drug-attributable falls in haematocrit</title><p id="Par44">The kinetics of the deposition of the deficits in haematocrit from 30% using the lowest recorded haematocrit in the first week of initiating treatment (DAFH) were evaluated as previously described for the general evaluation of kinetics of the disposition of anaemia in malarious children [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. Briefly, in all children, haematocrit values below pre-treatment levels following initiation of treatment and at follow-up were subtracted from pre-treatment haematocrit at each time of measurement until haematocrit rose to or above pre-treatment level and the resulting values plotted against time. The final haematocrit when pre-treatment level was reached was therefore zero in all patients with falls in haematocrit following initiation of treatment. However, the final haematocrit at the time when pre-treatment haematocrit level was reached was assumed to be 0.01% [<xref ref-type="bibr" rid="CR24">24</xref>]. The areas under the curve (AUC) of deficit in haematocrit from pre-treatment level versus time were obtained by trapezoidal rule using the computer program <italic>Turbo Ken</italic> (designed by Clinical Pharmacology Group, University of Southampton, United Kingdom) as previously described [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. AUC was also obtained manually by calculating the average haematocrit values between two consecutive time measurements and multiplying it by the time interval between the measurements, and summing up all the values, in a manner similar to that for the numerical estimation of area under a drug concentration-time curve (AUC) [<xref ref-type="bibr" rid="CR25">25</xref>]. The unit of quantification would be %.d, if haematocrit values were used or g/L.d if haemoglobin values were used. Haematocrit values may be converted to haemoglobin values by dividing by 3 [<xref ref-type="bibr" rid="CR26">26</xref>]. Semilogarithm plots of deficit in haematocrit from pre-treatment level versus time were plotted. The apparent terminal elimination rate constant (&#x003bb;) was obtained by least-square regression analysis of the post-peak log-linear part of the plot of deficit in haematocrit from pre-treatment level versus time. The apparent terminal half-time of DAFH (t<sub>1/2(DAFH)</sub>) was calculated from ln 2/&#x003bb; (that is, &#x003bb;t&#x02009;=&#x02009;0.693). Only children in whom haematocrit values were measured at least 3 times following a drug-attributable fall in haematocrit post-initiation of treatment were included in this evaluation.</p></sec><sec id="Sec8"><title>Statistical analysis</title><p id="Par45">Data were analyzed using version 6 of Epi-Info software [<xref ref-type="bibr" rid="CR27">27</xref>] and the statistical program SPSS for Windows version 20.0 [<xref ref-type="bibr" rid="CR28">28</xref>]. Variables considered in the analysis were related to the densities of <italic>P. falciparum</italic> asexual forms, haematocrit status at presentation and the values of DAFH and AUC<sub>(DAFH)</sub>. Proportions were compared by calculating &#x003c7;<sup>2</sup> using Yates&#x02019; correction, Fisher&#x02019;s exact or Mantel Haenszel tests. Normally distributed, continuous data were compared by Student&#x02019;s t test and analysis of variance (ANOVA). Kaplan-Meier estimator and pairwise log-rank tests were used to determine cumulative risk of anaemia occurring within 1&#x000a0;week post-treatment initiation with AL, AA or DHP. Stepwise multiple logistic regression models were used to test the association between: anaemia pre-treatment, normal haematocrit pre-treatment progressing to EAA within 1&#x000a0;week post-treatment initiation, malaria-attributable fall in haematocrit (MAFH) in excess of 4%, or drug-attributable fall in haematocrit (DAFH) in excess of 4%, and factors that were significant at univariate analysis. Correlation between the values of DAFH and AUC<sub>(DAFH)</sub> in the same patients was assessed by Pearson&#x02019;s correlation coefficient. Agreement between the values of DAFH and AUC<sub>(DAFH)</sub> was assessed by Bland-Altman analysis [<xref ref-type="bibr" rid="CR29">29</xref>]. Data were double entered serially using patients&#x02019; codes and were only analyzed at the end of the study.</p></sec></sec><sec id="Sec9"><title>Results</title><sec id="Sec10"><title>Characteristics of children enrolled in the study and parasite positivity following treatment</title><p id="Par46">Nine hundred and ninety two children were enrolled and randomized to AL (<italic>n</italic>&#x02009;=&#x02009;324), AA (<italic>n</italic>&#x02009;=&#x02009;321) or DHP (<italic>n</italic>&#x02009;=&#x02009;347) treatments. Of these children, haematocrit values were measured at presentation in 959 children (<italic>n</italic>&#x02009;=&#x02009;315, 307 and 337 in AL, AA and DHP treatments, respectively). Mean weight of 959 children enrolled in the study was 13.2&#x000a0;kg (95% CI 12.9&#x02013;13.4). The other characteristics of these children at presentation are shown in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. Two hundred and fifty six of the 959 children (27%) were aged &#x02264;24&#x000a0;months and 121 (13%) were aged &#x02264;15&#x000a0;months. One hundred and one (11%) had asexual parasitaemia &#x0003e;100,000&#x000a0;&#x003bc;L<sup>&#x02212;1</sup>. Overall, mean haematocrit at presentation was 30.6% (95% CI 30.3&#x02013;30.9). At presentation, anaemia was present in 355 of 959 children (37%) and it was mild, moderate or severe in 323 (33.7%), 30 (3.1%) or 2 children (0.2%), respectively (Table <xref rid="Tab1" ref-type="table">1</xref>). Overall, asexual parasite positivity on day 3 was 29 of 959 children (3%) and it was similar in all treatments&#x000a0;groups [11 of 315 children (3%), 12 of 307 children (4%), and 6 of 337 children (2%) in AL-, AA- and DHP-treated children, respectively, <italic>P</italic>&#x02009;=&#x02009;0.24].<table-wrap id="Tab1"><label>Table 1</label><caption><p>Characteristics of the 959 children enrolled in the study of risk factors for anaemia in uncomplicated falciparum malaria</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Variables</th><th rowspan="2">No. with enrolment haematocrit, n (%)<sup>a</sup>
</th><th rowspan="2">Enrolment haematocrit, mean [95% CI]</th><th colspan="4">Anaemia (haematocrit &#x0003c;30%) at presentation, n (%)<sup>a</sup>
</th></tr><tr><th>ALL</th><th>Mild</th><th>Moderate</th><th>Severe</th></tr></thead><tbody><tr><td>Total</td><td>959 (96.7)</td><td>30.6 [30.3&#x02013;30.9]</td><td>355 (37)</td><td>323 (33.7)</td><td>30 (3.1)</td><td>2 (0.2)</td></tr><tr><td>Male</td><td>522 (52.6)</td><td>30.5 [30.1&#x02013;31]</td><td>197 (20.5)</td><td>182 (19)</td><td>14 (1.5)</td><td>1 (0.1)</td></tr><tr><td>Female</td><td>437 (44.1)</td><td>30.7 [30.2&#x02013;31.2]</td><td>158 (16.5)</td><td>141 (14.7)</td><td>16 (1.6)</td><td>1 (0.1)</td></tr><tr><td>Aged<sup>b</sup> &#x02264; 15&#x000a0;months</td><td>121 (12.6)</td><td>29 [28.1&#x02013;30]</td><td>56 (5.8)</td><td>48 (5)</td><td>8 (0.8)</td><td>0 (0)</td></tr><tr><td>&#x02003;&#x02264;&#x02009;24&#x000a0;months</td><td>256 (25.8)</td><td>29.7 [29.1&#x02013;30.3]</td><td>108 (11.3)</td><td>93 (9.7)</td><td>14 (1.5)</td><td>1 (0.1)</td></tr><tr><td>&#x02003;&#x0003e;&#x02009;24&#x000a0;months</td><td>695 (70.1)</td><td>30.9 [30.6&#x02013;31.2]</td><td>244 (25.4)</td><td>228 (23.8)</td><td>15 (1.6)</td><td>1 (0.1)</td></tr><tr><td colspan="7">Asexual parasitaemia<sup>c</sup>
</td></tr><tr><td>&#x02003;&#x02264;&#x02009;25,000&#x000a0;&#x003bc;L<sup>&#x02212;1</sup>
</td><td>559 (52.3)</td><td>30.6 [29.6&#x02013;30.4]</td><td>225 (23.5)</td><td>203 (21.2)</td><td>20 (2.1)</td><td>2 (0.2)</td></tr><tr><td>&#x02003;&#x0003e;&#x02009;25,000&#x02013;50,000&#x000a0;&#x003bc;L<sup>&#x02212;1</sup>
</td><td>141 (14.7)</td><td>31.2 [30.3&#x02013;32.2]</td><td>41 (4.3)</td><td>35 (3.6)</td><td>6 (0.6)</td><td>0 (0)</td></tr><tr><td>&#x02003;&#x0003e;&#x02009;50,000&#x02013;100,000&#x000a0;&#x003bc;L<sup>&#x02212;1</sup>
</td><td>152 (15.8)</td><td>31.3 [30.4&#x02013;32.1]</td><td>52 (5.4)</td><td>50 (5.2)</td><td>2 (0.2)</td><td>0 (0)</td></tr><tr><td>&#x02003;&#x0003e;&#x02009;100,000&#x000a0;&#x003bc;L<sup>&#x02212;1</sup>
</td><td>101 (10.5)</td><td>31.4 [30.4&#x02013;32.4]</td><td>35 (3.6)</td><td>33 (3.4)</td><td>2 (0.2)</td><td>0 (0)</td></tr><tr><td colspan="7">Gametocytaemia</td></tr><tr><td>&#x02003;Present</td><td>47 (4.7)</td><td>28.8 [27.6&#x02013;30]</td><td>22 (2.3)</td><td>20 (2.1)</td><td>2 (0.2)</td><td>0 (0)</td></tr><tr><td>&#x02003;Absent</td><td>912 (91.9)</td><td>30.7 [30.3&#x02013;31]</td><td>333 (34.7)</td><td>303 (31.6)</td><td>28 (2.9)</td><td>2 (0.2)</td></tr><tr><td colspan="7">Region of enrolment</td></tr><tr><td>&#x02003;Eastern flank<sup>d</sup>
</td><td>503 (50.7)</td><td>30.6 [30.1&#x02013;31.1]</td><td>175 (18.2)</td><td>152 (15.8)</td><td>21 (2.2)</td><td>2 (0.2)</td></tr><tr><td>&#x02003;Western flank<sup>e</sup>
</td><td>456 (46)</td><td>30.6 [30.1&#x02013;31]</td><td>180 (18.8)</td><td>171 (17.8)</td><td>9 (0.9)</td><td>0 (0)</td></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup>values in parenthesis are expressed as percentage of 992 children randomized</p><p>
<sup>b</sup>data for age not available in eight children</p><p>
<sup>c</sup>data for asexual parasitaemia not available in 6 children</p><p>
<sup>d</sup>Eastern flank includes: Numan, Nena, Ogbia and Ogwa in Adamawa, Anambra, Bayelsa and Imo States, respectively</p><p>
<sup>e</sup>Western flank includes: Kura, Ilorin, Ibadan and Bodinga in Kano, Kwara, Oyo and Sokoto States, respectively</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec11"><title>Factors contributing to anaemia at presentation</title><p id="Par47">Factors associated with anaemia at presentation are presented in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>. In a univariate analysis, an age&#x02009;&#x02264;&#x02009;15&#x000a0;months, duration of illness &#x0003e;2&#x000a0;days, and enrolment asexual parasitaemia &#x02264;10,000&#x000a0;&#x003bc;L<sup>&#x02212;1</sup> were associated with anaemia at presentation. In a multivariate analysis, duration of illness &#x0003e;2&#x000a0;days and an enrolment asexual parasitaemia &#x02264;10,000&#x000a0;&#x003bc;L<sup>&#x02212;1</sup> were independent predictors of anaemia at presentation (Table <xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Predictors of anaemia at presentation in children &#x0003c;5&#x000a0;years with uncomplicated falciparum malaria</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>Total no.</th><th>No. with anaemia at presentation</th><th>OR (95% CI)</th><th>
<italic>P</italic> value</th><th>AOR (95% CI)</th><th>
<italic>P</italic> value</th></tr></thead><tbody><tr><td colspan="7">Gender</td></tr><tr><td>&#x02003;Female</td><td>437</td><td>158</td><td>1</td><td/><td/><td/></tr><tr><td>&#x02003;Male</td><td>522</td><td>197</td><td>1.1 (0.8&#x02013;1.4)</td><td char="." align="char">0.66</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td colspan="7">Age (months)</td></tr><tr><td>&#x02003;&#x0003e;&#x02009;15</td><td>837</td><td>296</td><td>1</td><td/><td>1</td><td/></tr><tr><td>&#x02003;&#x02264;&#x02009;15</td><td>114</td><td>56</td><td>1.8 (1.2&#x02013;2.6)</td><td char="." align="char">0.01</td><td>1.5 (0.9&#x02013;2.5)</td><td>0.09</td></tr><tr><td colspan="7">Duration of illness (days)</td></tr><tr><td>&#x02003;&#x02264;&#x02009;2</td><td>295</td><td>92</td><td>1</td><td/><td>1</td><td/></tr><tr><td>&#x02003;&#x0003e;&#x02009;2</td><td>330</td><td>138</td><td>1.6 (1.1&#x02013;2.2)</td><td char="." align="char">0.01</td><td>1.5 (1.1&#x02013;2.1)</td><td>0.02</td></tr><tr><td colspan="7">Enrolment body temperature (&#x000b0;C)</td></tr><tr><td>&#x02003;&#x02264;&#x02009;37.4</td><td>357</td><td>143</td><td>1</td><td/><td/><td/></tr><tr><td>&#x02003;&#x0003e;&#x02009;37.4</td><td>601</td><td>211</td><td>0.8 (0.6&#x02013;1.1)</td><td char="." align="char">0.14</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td colspan="7">History of fever</td></tr><tr><td>&#x02003;Absent</td><td>169</td><td>70</td><td>1</td><td/><td/><td/></tr><tr><td>&#x02003;Present</td><td>789</td><td>284</td><td>1.2 (0.9&#x02013;1.8)</td><td char="." align="char">0.22</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td colspan="7">Asexual parasitaemia (&#x003bc;L<sup>&#x02212;1</sup>)</td></tr><tr><td>&#x02003;&#x0003e;&#x02009;10,000</td><td>389</td><td>160</td><td>1</td><td/><td>1</td><td/></tr><tr><td>&#x02003;&#x02264;&#x02009;10,000</td><td>564</td><td>193</td><td>1.3 (1.1&#x02013;1.8)</td><td char="." align="char">0.003</td><td>1.5 (1.1&#x02013;2.2)</td><td>0.02</td></tr><tr><td colspan="7">Gametocyte carriage at presentation</td></tr><tr><td>&#x02003;Absent</td><td>912</td><td>333</td><td>1</td><td/><td/><td/></tr><tr><td>&#x02003;Present</td><td>47</td><td>22</td><td>1.5 (0.6&#x02013;2.8)</td><td char="." align="char">0.2</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td colspan="7">Season of enrolment</td></tr><tr><td>&#x02003;Dry (November&#x02013;March)</td><td>69</td><td>24</td><td>1</td><td/><td/><td/></tr><tr><td>&#x02003;Wet (April&#x02013;October)</td><td>890</td><td>331</td><td>1.1 (0.7&#x02013;1.9)</td><td char="." align="char">0.79</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td colspan="7">Region of enrolment</td></tr><tr><td>&#x02003;Eastern flank<sup>a</sup>
</td><td>456</td><td>180</td><td>1</td><td/><td/><td/></tr><tr><td>&#x02003;Western flank<sup>b</sup>
</td><td>503</td><td>175</td><td>0.8 (0.6&#x02013;1.1)</td><td char="." align="char">0.15</td><td>&#x02013;</td><td>&#x02013;</td></tr></tbody></table><table-wrap-foot><p>
<italic>OR</italic> odd ratio, <italic>AOR</italic> adjusted odd ratio, <italic>CI</italic> confidence interval</p><p>
<sup>a</sup>Eastern flank includes: Numan, Neni, Ogbia and Ogwa in Adamawa, Anambra, Bayelsa and Imo States, respectively</p><p>
<sup>b</sup>Western flank includes: Kura, Ilorin, Ibadan and Bodinga in Kano, Kwara, Oyo and Sokoto States, respectively</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec12"><title>Recovery from pre-treatment anaemia</title><p id="Par48">Data for the evaluation of recovery from pre-treatment anaemia were available in 318 of 355 children. Of these children, 142, 101, 58, 26, 8 and 3 children recovered from their anaemia within 1, 2, 3, 4, 5 and 6&#x000a0;weeks post-treatment initiation, respectively. Overall, mean anaemia recovery time was 11.5&#x000a0;days (95% CI 10.5&#x02013;12.5, <italic>n</italic>&#x02009;=&#x02009;308). Mean anaemia recovery time was significantly longer in DHP-treated children compared with AL- and AA-treated children [13.3&#x000a0;days (95% CI 11.5&#x02013;15.2, <italic>n</italic>&#x02009;=&#x02009;95) versus 11.7&#x000a0;days (95% CI 9.9&#x02013;13.6, <italic>n</italic>&#x02009;=&#x02009;108) versus 9.5&#x000a0;days (95% CI 8&#x02013;11, <italic>n</italic>&#x02009;=&#x02009;105) respectively, <italic>P</italic>&#x02009;=&#x02009;0.01]. Ten children did not recover from their pre-treatment anaemia during the entire follow-up period.</p></sec><sec id="Sec13"><title>Factors contributing to progression from normal haematocrit pre-treatment to anaemia within 1&#x000a0;week post &#x02013;treatment initiation (early-appearing anaemia)</title><p id="Par49">Data for evaluation progression from normal haematocrit pre-treatment to an early-appearing anaemia (EAA) within 1&#x000a0;week post-treatment initiation were available in 604 children. Of these children, 301 children (50%) progressed to anaemia within 1&#x000a0;week post-treatment initiation. The proportions of non-anaemic children who subsequently progressed to anaemia within 1&#x000a0;week of starting treatment were similar with all three treatments (101 of 191 (53%) versus 90 of 187 (48%) versus 110 of 226 children (49%) in AL, AA and DHP treatments, respectively <italic>P</italic>&#x02009;=&#x02009;0.59). The probabilities of progression to anaemia 1&#x000a0;week post-treatment initiation were also similar in all three treatments (Log-rank statistic&#x02009;=&#x02009;1.24; <italic>P</italic>&#x02009;=&#x02009;0.54, Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). Factors contributing to progression to anaemia within 1&#x000a0;week are shown in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>. In a univariate analysis, an age&#x02009;&#x02264;&#x02009;15&#x000a0;months, history of fever at presentation, enrolment haematocrit &#x02264;35% and persistent asexual parasitaemia till 1 or 2&#x000a0;days post-treatment initiation were significantly associated with progression to anaemia within 1&#x000a0;week post-initiation of treatment. In a multivariate analysis, an age&#x02009;&#x02264;&#x02009;15&#x000a0;months, history of fever at presentation and enrolment haematocrit &#x02264;35% were independent predictors of progression to anaemia within 1&#x000a0;week (Table <xref rid="Tab3" ref-type="table">3</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>Kaplan-Meier survival estimates of anaemia occurring within 1&#x000a0;week following treatment with artesunate-amodiaquine (AA, blue line), artemether-lumefantrine (AL, green line) or dihydroartemisinin-piperaquine (DHP, yellow line) in children who were non-anaemic pre-treatment. Log-rank statistic&#x02009;=&#x02009;1.24, <italic>P</italic>&#x02009;=&#x02009;0.54. Pooled data from all sentinel sites. The probabilities of progression to anaemia within 1&#x000a0;week post-treatment were similar with all three treatments</p></caption><graphic xlink:href="12879_2017_2876_Fig2_HTML" id="MO2"/></fig>
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Predictors of progression from normal haematocrit pre-treatment to anaemia within one week post-initiation of artemisinin-based combination treatments in &#x0003c;5&#x000a0;year-old children with uncomplicated falciparum malaria</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>Total no.</th><th>No. with anaemia 1&#x000a0;week post-initiation of ACTs</th><th>OR (95% CI)</th><th>P value</th><th>AOR (95% CI)</th><th>
<italic>P</italic> value</th></tr></thead><tbody><tr><td colspan="7">Gender</td></tr><tr><td>&#x02003;Female</td><td>278</td><td>132</td><td>1</td><td/><td/><td/></tr><tr><td>&#x02003;Male</td><td>325</td><td>168</td><td>0.8 (0.6&#x02013;1.2)</td><td>0.34</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td colspan="7">Age (month)</td></tr><tr><td>&#x02003;&#x0003e;&#x02009;15</td><td>541</td><td>255</td><td>1</td><td/><td>1</td><td/></tr><tr><td>&#x02003;&#x02264;&#x02009;15</td><td>58</td><td>42</td><td>2.9 (1.6&#x02013;5.4)</td><td>&#x0003c; 0.0001</td><td>2.5 (1.4&#x02013;4.7)</td><td>0.003</td></tr><tr><td colspan="7">Duration of illness (day)</td></tr><tr><td>&#x02003;&#x02264;&#x02009;2</td><td>203</td><td>101</td><td>1</td><td/><td/><td/></tr><tr><td>&#x02003;&#x0003e;&#x02009;2</td><td>192</td><td>100</td><td>1.0 (0.7&#x02013;1.6)</td><td>1.0</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td colspan="7">Enrolment body temperature (&#x000b0;C)</td></tr><tr><td>&#x02003;&#x02264;&#x02009;37.4</td><td>214</td><td>104</td><td>1</td><td/><td/><td/></tr><tr><td>&#x02003;&#x0003e;&#x02009;37.4</td><td>390</td><td>197</td><td>1.1 (1.0&#x02013;1.9)</td><td>0.71</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td colspan="7">History of fever at enrolment</td></tr><tr><td>&#x02003;Absent</td><td>99</td><td>39</td><td>1</td><td/><td>1</td><td/></tr><tr><td>&#x02003;Present</td><td>505</td><td>262</td><td>1.7 (1.1&#x02013;2.6)</td><td>0.03</td><td>1.8 (1.1&#x02013;2.9)</td><td>0.01</td></tr><tr><td colspan="7">Fever on day 1</td></tr><tr><td>&#x02003;Absent</td><td>501</td><td>255</td><td>1</td><td/><td/><td/></tr><tr><td>&#x02003;Present</td><td>70</td><td>38</td><td>1.1 (0.7&#x02013;1.9)</td><td>0.69</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td colspan="7">Haematocrit (%)</td></tr><tr><td>&#x02003;&#x0003e;&#x02009;35</td><td>140</td><td>42</td><td>1</td><td/><td>1</td><td/></tr><tr><td>&#x02003;&#x02264;&#x02009;35</td><td>464</td><td>259</td><td>2.9 (2.0&#x02013;4.4)</td><td>&#x0003c; 0.0001</td><td>2.9 (1.9&#x02013;4.4)</td><td>&#x0003c;0.0001</td></tr><tr><td colspan="7">Parasitaemia (&#x003bc;L<sup>&#x02212;1</sup>)</td></tr><tr><td>&#x02003;&#x02264;&#x02009;50,000</td><td>434</td><td>213</td><td>1</td><td/><td/><td/></tr><tr><td>&#x02003;&#x0003e;&#x02009;50,000</td><td>166</td><td>87</td><td>1.1 (0.8&#x02013;1.6)</td><td>0.52</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td colspan="7">Parasitaemia on day 1</td></tr><tr><td>&#x02003;Absent</td><td>244</td><td>111</td><td>1</td><td/><td/><td/></tr><tr><td>&#x02003;Present</td><td>360</td><td>190</td><td>1.3 (1.0&#x02013;1.9)</td><td>0.09</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td colspan="7">Parasitaemia day 1 or 2</td></tr><tr><td>&#x02003;Absent</td><td>233</td><td>104</td><td>1</td><td/><td>1</td><td/></tr><tr><td>&#x02003;Present</td><td>371</td><td>197</td><td>1.4 (1.0&#x02013;2.0)</td><td>0.04</td><td>1.3 (0.9&#x02013;1.9)</td><td>0.11</td></tr><tr><td colspan="7">Gametocytaemia</td></tr><tr><td>&#x02003;Absent</td><td>579</td><td>289</td><td>1</td><td/><td/><td/></tr><tr><td>&#x02003;Present</td><td>25</td><td>12</td><td>0.9 (0.4&#x02013;2.1)</td><td>1.0</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td colspan="7">Parasite clearance time (day)</td></tr><tr><td>&#x02003;&#x02264;&#x02009;2</td><td>468</td><td>234</td><td>1</td><td/><td/><td/></tr><tr><td>&#x02003;&#x0003e;&#x02009;2</td><td>136</td><td>67</td><td>1.0 (0.7&#x02013;1.4)</td><td>0.96</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td colspan="7">Fever clearance time (day)</td></tr><tr><td>&#x02003;&#x02264;&#x02009;2</td><td>367</td><td>186</td><td>1</td><td/><td/><td/></tr><tr><td>&#x02003;&#x0003e;&#x02009;2</td><td>13</td><td>9</td><td>1.9 (0.9&#x02013;4.3)</td><td>0.13</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td colspan="7">Season of enrolment</td></tr><tr><td>&#x02003;Dry (November&#x02013;March)</td><td>45</td><td>17</td><td>1</td><td/><td/><td/></tr><tr><td>&#x02003;Wet (April&#x02013;October)</td><td>559</td><td>284</td><td>1.7 (0.9&#x02013;3.2)</td><td>0.13</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td colspan="7">Drug treatment</td></tr><tr><td>&#x02003;DHP</td><td>226</td><td>110</td><td>1</td><td/><td/><td/></tr><tr><td>&#x02003;AL</td><td>191</td><td>101</td><td>1.2 (0.8&#x02013;1.7)</td><td>0.49</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td>&#x02003;AA</td><td>187</td><td>90</td><td>1.0 (0.7&#x02013;1.4)</td><td>1.0</td><td/><td/></tr></tbody></table><table-wrap-foot><p>
<italic>OR</italic> odd ratio, <italic>AOR</italic> adjusted odd ratio, <italic>CI</italic> confidence interval, <italic>DHP</italic> dihydroartemisinin-piperaquine, <italic>AL</italic> artemether-lumefantrine, <italic>AA</italic> artesunate-amodiaquine, <italic>ACTs</italic> artemisinin-based combination treatments</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec14"><title>Recovery from early-appearing anaemia</title><p id="Par50">Data for evaluation of recovery from EAA were available in 275 of 301 children. Of these children, 166, 71, 19, 9, 3 and 2 children recovered at 1, 2, 3, 4, 5 and 6&#x000a0;weeks post-treatment initiation, respectively. Overall, mean anaemia recovery time was 8.4&#x000a0;days (95% CI 7.4&#x02013;9.3, <italic>n</italic>&#x02009;=&#x02009;270). Anaemia recovery times were similar with all three treatments [8.6&#x000a0;days (95% CI 6.8&#x02013;10.4, <italic>n</italic>&#x02009;=&#x02009;91) versus 7.3&#x000a0;days (95% CI 6&#x02013;8.5, <italic>n</italic>&#x02009;=&#x02009;80) versus 9.5&#x000a0;days (95% CI 8&#x02013;11, <italic>n</italic>&#x02009;=&#x02009;99) in AL-, AA- and DHP-treated children, respectively <italic>P</italic>&#x02009;=&#x02009;0.14]. Five children did not recover from their anaemia during the entire follow-up period. Anaemia recovery time in children who progressed to EAA was significantly shorter than anaemia recovery time of children who were anaemic at presentation [8.4&#x000a0;days (95% CI 7.4&#x02013;9.3, <italic>n</italic>&#x02009;=&#x02009;270) versus 11.5&#x000a0;days (95% CI 10.5&#x02013;12.5, <italic>n</italic>&#x02009;=&#x02009;308), respectively <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001].</p></sec><sec id="Sec15"><title>Time-course of haematocrit following artemisinin-based combination treatments</title><p id="Par51">Figure&#x000a0;<xref rid="Fig3" ref-type="fig">3a</xref> shows the time-course of haematocrit in children who were non-anaemic at presentation and those who were anaemic at presentation following ACTs. Following treatment, there was little or no fall in haematocrit in anaemic children compared to non-anaemic children indicating little or no drug-attributable falls in the former. Additionally, the rate of rise in haematocrit was rather &#x02018;steep&#x02019; in anaemic children following treatment. Following initiation of treatment, overall, mean time to nadir hematocrit was reached 2.2&#x000a0;days (95% CI 2.1&#x02013;2.4, <italic>n</italic>&#x02009;=&#x02009;719) after initiation of treatment and it was significantly shorter in anaemic compared to non-anaemic children at presentation [1.4&#x000a0;days (95% CI 1.3&#x02013;1.7, <italic>n</italic>&#x02009;=&#x02009;213) versus 2.6&#x000a0;days (95% CI 2.5&#x02013;2.8, <italic>n</italic>&#x02009;=&#x02009;506) in anaemic and non-anaemic children, respectively, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001]. Compared with pre-treatment haematocrit, falls in haematocrit to nadir levels were significantly lower in anaemic compared to non-anaemic children [3.4% (95% CI 3.1&#x02013;3.8 <italic>n</italic>&#x02009;=&#x02009;213) versus 5.6% (95% CI 5.3&#x02013;6, <italic>n</italic>&#x02009;=&#x02009;506, respectively, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001]. When falls to nadir haematocrits were expressed as percentages of pre-treatment haematocrit levels, falls were significantly higher in non-anaemic compared to anaemic children [16.3% (95% CI 15.5&#x02013;17.2, <italic>n</italic>&#x02009;=&#x02009;506) versus 13.1% (95% CI 11.9&#x02013;14.4, <italic>n</italic>&#x02009;=&#x02009;213), respectively <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001]. The time-course of haematocrit were similar with all three treatments (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3b</xref>). Mean time to nadir haematocrit was also similar with all three treatments [2.1&#x000a0;days (95% CI16.8&#x02013;2.3, <italic>n</italic>&#x02009;=&#x02009;234) versus 2.2&#x000a0;days (95% CI 2&#x02013;2.4, <italic>n</italic>&#x02009;=&#x02009;234) versus 2.4&#x000a0;days (95% CI 2.1&#x02013;2.6, <italic>n</italic>&#x02009;=&#x02009;251) in AL-, AA- and DHP-treated children, respectively <italic>P</italic>&#x02009;=&#x02009;0.24]. Similarly, when falls to nadir haematocrits were expressed as percentages of pre-treatment haematocrit levels, falls were not significantly different between all three treatments [15.3% (95% CI 14.1&#x02013;16.6, <italic>n</italic>&#x02009;=&#x02009;234) versus 14.8% (95% CI 13.6&#x02013;16.1, <italic>n</italic>&#x02009;=&#x02009;234) versus 16% (95% CI 14.7&#x02013;17.2, <italic>n</italic>&#x02009;=&#x02009;251) in AL-, AA- and DHP-treated children, respectively <italic>P</italic>&#x02009;=&#x02009;0.44].<fig id="Fig3"><label>Fig. 3</label><caption><p>Time-course of haematocrit in (<bold>a</bold>) all (black line), anaemic (green line) and non-anaemic (blue line) children following artemisinin-based combination treatments, and (<bold>b</bold>) in children treated with artemether-lumefantrine (red line), artesunate-amodiaquine (green line) or dihydroartemisinin-piperaquine (blue line). Values represent means of haematocrit and standard error of means. Note little or no fall in haematocrit in anaemic children following treatment</p></caption><graphic xlink:href="12879_2017_2876_Fig3_HTML" id="MO3"/></fig>
</p></sec><sec id="Sec16"><title>Malaria-attributable fall in haematocrit</title><p id="Par52">Data for estimation of MAFH were available in 748 children (428 and 320 non-anemic and anaemic children, respectively). In these children, there was no malaria-attributable fall in haematocrit following infection in 54 children (49 and 5 non-anaemic and anaemic children, respectively). The proportion of children with no MAFH following treatment was significantly higher in non-anaemic children compared with anaemic children at presentation (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001). Varying degrees of malaria-attributable falls in haematocrit were seen in 694 children (379 and 315 in non-anaemic and anaemic children, respectively). Overall, mean MAFH was 6.8% (95% CI 6.5&#x02013;7.2, <italic>n</italic>&#x02009;=&#x02009;694) and it was significantly lower in non-anemic compared to anaemic children [4.6% (95% CI 4.3&#x02013;4.9, <italic>n</italic>&#x02009;=&#x02009;379) versus 9.5% (95% CI 9&#x02013;10, <italic>n</italic>&#x02009;=&#x02009;315), respectively <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001)].</p><p id="Par53">MAFH in excess of 4% occurred in 446 of 694 children (64.3%). The proportion of non-anaemic children with MAFH in excess of 4% was significantly lower compared to anaemic children (170 of 379 children (44.9%) versus 276 of 315 children (87.6%), respectively; <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001) indicating a greater burden of a single episode of infection was borne by anaemic compared to non-anaemic children. Mean MAFH in non-anaemic children were similar for all three treatments [4.8% (95% CI 4.3&#x02013;5.3, <italic>n</italic>&#x02009;=&#x02009;117) versus 4.8% (95% CI 4.3&#x02013;5.3, <italic>n</italic>&#x02009;=&#x02009;127) versus 4.8% (95% CI 4.3&#x02013;5.3, <italic>n</italic>&#x02009;=&#x02009;135) in AL, AA and DHP- treated children, respectively, <italic>P</italic>&#x02009;=&#x02009;0.33]. Similarly, mean MAFH in anaemic children were similar for all three treatments [9.4% (95% CI 8.6&#x02013;10.2, <italic>n</italic>&#x02009;=&#x02009;112) versus 9.8% (95% CI 8.9&#x02013;10.6, <italic>n</italic>&#x02009;=&#x02009;107) versus 9.3% (95% CI 8.3&#x02013;10.3, <italic>n</italic>&#x02009;=&#x02009;96) in AL, AA and DHP -treated children, respectively, <italic>P</italic>&#x02009;=&#x02009;0.75]. The proportions of children with MAFH in excess of 4% were also similar for all three treatments in non-anaemic [56 of 117 versus 58 of 127 versus 56 of 135 children in AL. AA and DHP -treated children, respectively, <italic>P</italic>&#x02009;=&#x02009;0.58] and anaemic children [98 of 112 versus 97 of 107 versus 81 of 96 children in AL-, AA- and DHP-treated children, respectively, <italic>P</italic>&#x02009;=&#x02009;0.4].</p><p id="Par54">Factors associated with MAFH in excess of 4% are shown in Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>. In a univariate analysis, an age&#x02009;&#x02264;&#x02009;38&#x000a0;months, anaemia at presentation, enrolment parasitaemia &#x02264;50,000&#x000a0;&#x003bc;L<sup>&#x02212;1</sup>, parasitaemia 1&#x000a0;day after start of treatment and gametocytaemia within 1&#x000a0;week were associated with MAFH &#x0003e;4%. In a multivariate analysis, anaemia at presentation, enrolment parasitaemia &#x02264;50,000&#x000a0;&#x003bc;L<sup>&#x02212;1</sup>, parasitaemia 1&#x000a0;day after start of treatments and gametocytaemia within 1&#x000a0;week were independent predictors of MAFH &#x0003e;4% (Table <xref rid="Tab4" ref-type="table">4</xref>).<table-wrap id="Tab4"><label>Table 4</label><caption><p>Predictors of malaria-attributable fall in haematocrit (MAFH) in excess of 4% in &#x0003c;5&#x000a0;year-old children with uncomplicated falciparum malaria following artemisinin-based combination treatments</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>Total no.</th><th>No. with MAFH &#x0003e;4%</th><th>OR (95% CI)</th><th>
<italic>P</italic> value</th><th>AOR (95% CI)</th><th>
<italic>P</italic> value</th></tr></thead><tbody><tr><td colspan="7">Gender</td></tr><tr><td>&#x02003;Female</td><td>314</td><td>203</td><td>1</td><td/><td/><td/></tr><tr><td>&#x02003;Male</td><td>380</td><td>243</td><td>1.0 (0.7&#x02013;1.3)</td><td>0.91</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td colspan="7">Age (month)</td></tr><tr><td>&#x02003;&#x0003e;&#x02009;38</td><td>354</td><td>213</td><td>1</td><td/><td>1</td><td/></tr><tr><td>&#x02003;&#x02264;&#x02009;38</td><td>335</td><td>228</td><td>1.4 (1.0&#x02013;1.9)</td><td>0.04</td><td>2.1 (0.8&#x02013;1.6)</td><td>0.53</td></tr><tr><td colspan="7">Duration of illness (day)</td></tr><tr><td>&#x02003;&#x02264;&#x02009;2</td><td>200</td><td>120</td><td>1</td><td/><td/><td/></tr><tr><td>&#x02003;&#x0003e;&#x02009;2</td><td>274</td><td>180</td><td>1.1 (0.7&#x02013;1.6)</td><td>0.78</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td colspan="7">Enrolment body temperature (&#x000b0;C)</td></tr><tr><td>&#x02003;&#x02264;&#x02009;37.4</td><td>264</td><td>173</td><td>1</td><td/><td/><td/></tr><tr><td>&#x02003;&#x0003e;&#x02009;37.4</td><td>429</td><td>272</td><td>0.9 (0.7&#x02013;1.3)</td><td>0.63</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td colspan="7">History of fever at enrolment</td></tr><tr><td>&#x02003;Absent</td><td>123</td><td>77</td><td>1</td><td/><td/><td/></tr><tr><td>&#x02003;Present</td><td>571</td><td>368</td><td>1.1 (0.7&#x02013;1.6)</td><td>0.78</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td colspan="7">Fever on day 1</td></tr><tr><td>&#x02003;Absent</td><td>619</td><td>398</td><td>1</td><td/><td/><td/></tr><tr><td>&#x02003;Present</td><td>62</td><td>38</td><td>0.9 (0.5&#x02013;1.5)</td><td>0.74</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td colspan="7">Haematocrit (%)</td></tr><tr><td>&#x02003;&#x02265;&#x02009;30</td><td>379</td><td>170</td><td>1</td><td/><td>1</td><td/></tr><tr><td>&#x02003;&#x0003c;&#x02009;30</td><td>315</td><td>276</td><td>8.7 (5.9&#x02013;12.9)</td><td>&#x0003c; 0.0001</td><td>9.4 (6.3&#x02013;14.1)</td><td>&#x0003c;0.0001</td></tr><tr><td colspan="7">Parasitaemia (&#x003bc;L<sup>&#x02212;1</sup>)</td></tr><tr><td>&#x02003;&#x0003e;&#x02009;50,000</td><td>171</td><td>91</td><td>1</td><td/><td>1</td><td/></tr><tr><td>&#x02003;&#x02264;&#x02009;50,000</td><td>521</td><td>355</td><td>1.9 (1.3&#x02013;2.7)</td><td>0.001</td><td>1.9 (1.3&#x02013;2.9</td><td>0.002</td></tr><tr><td colspan="7">Parasitaemia on day 1</td></tr><tr><td>&#x02003;Absent</td><td>380</td><td>228</td><td>1</td><td/><td>1</td><td/></tr><tr><td>&#x02003;Present</td><td>314</td><td>218</td><td>1.5 (1.1&#x02013;2.1)</td><td>0.01</td><td>1.6 (1.1&#x02013;2.3)</td><td>0.01</td></tr><tr><td colspan="7">Gametocytaemia (D0&#x02013;7)</td></tr><tr><td>&#x02003;Absent</td><td>621</td><td>390</td><td>1</td><td/><td>1</td><td/></tr><tr><td>&#x02003;Present</td><td>73</td><td>56</td><td>2.0 (1.1&#x02013;3.4)</td><td>0.027</td><td>2.0 (1.0&#x02013;3.7)</td><td>0.04</td></tr><tr><td colspan="7">Parasite clearance time (days)</td></tr><tr><td>&#x02003;&#x02264;&#x02009;2</td><td>551</td><td>357</td><td>1</td><td/><td/><td/></tr><tr><td>&#x02003;&#x0003e;&#x02009;2</td><td>142</td><td>89</td><td>0.9 (0.6&#x02013;1.3)</td><td>0.71</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td colspan="7">Fever clearance time (days)</td></tr><tr><td>&#x02003;&#x02264;&#x02009;2</td><td>416</td><td>261</td><td>1</td><td/><td/><td/></tr><tr><td>&#x02003;&#x0003e;&#x02009;2</td><td>13</td><td>11</td><td>3.3 (0.7&#x02013;14.9)</td><td>0.19</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td colspan="7">Season of enrolment</td></tr><tr><td>&#x02003;Dry (November&#x02013;March)</td><td>41</td><td>23</td><td>1</td><td/><td/><td/></tr><tr><td>&#x02003;Wet (April&#x02013;October)</td><td>653</td><td>423</td><td>1.4 (0.8&#x02013;2.7)</td><td>0.34</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td colspan="7">Drug treatment</td></tr><tr><td>&#x02003;DHP</td><td>231</td><td>137</td><td>1</td><td/><td/><td/></tr><tr><td>&#x02003;AL</td><td>229</td><td>154</td><td>1.4 (1.0&#x02013;2.1)</td><td>0.1</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td>&#x02003;AA</td><td>234</td><td>155</td><td>1.3 (0.9&#x02013;2.0)</td><td>0.15</td><td/><td/></tr></tbody></table><table-wrap-foot><p>
<italic>OR</italic> odd ratio, <italic>AOR</italic> adjusted odd ratio, <italic>CI</italic> confidence interval, <italic>MAFH</italic> malaria-attributable fall in haematocrit, <italic>DHP</italic> dihydroartemisinin-piperaquine, <italic>AL</italic> artemether-lumefantrine, <italic>AA</italic> artesunate-amodiaquine. D0&#x02013;7, day 0&#x02013;7</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec17"><title>Drug-attributable falls in haematocrit</title><p id="Par55">Data for estimation of DAFH were available in 929 children (588 and 341 non-anaemic and anaemic children at presentation, respectively). In these children, there was no DAFH following treatment in 210 children (82 and 128 non-anaemic and anaemic children, respectively). The proportions of children without DAFH were significantly higher in anaemic compared to non-anaemic children (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001, Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>). Varying degrees of DAFH occurred in 719 children (506 and 213 non-anaemic and anaemic children, respectively; Fig. <xref rid="Fig4" ref-type="fig">4</xref>). Overall, lowest falls from pre-treatment levels were seen on day 1, 2 or 3 in 232, 217 or 158 children, respectively. Overall, mean DAFH was 5% (95% CI 4.7&#x02013;5.2, <italic>n</italic>&#x02009;=&#x02009;719) and it was significantly higher in non-anaemic compared to anaemic children [5.6% (95% CI 5.3&#x02013;5.9, <italic>n</italic>&#x02009;=&#x02009;506) versus 3.4% (95% CI 3.1&#x02013;3.8, <italic>n</italic>&#x02009;=&#x02009;213), <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001; Fig. <xref rid="Fig4" ref-type="fig">4</xref>) [see also time-course of changes in haematocrit following treatments above]. DAFH in excess of 4% occurred in 385 of 719 children (53.5%) [279 of 506 (55.1%) and 55 of 213 (25.8%) in non-anaemic and anaemic children, respectively]. The proportion of non-anaemic children with DAFH in excess of 4% was significantly higher than in anaemic children (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001) indicating relative lack of conservation in non-anaemic children and relative conservation in anaemic children.<fig id="Fig4"><label>Fig. 4</label><caption><p>Drug-attributable falls in haematocrit in anaemic&#x000a0;<bold>(a)</bold> and non-anaemic children&#x000a0;<bold>(b)</bold> following artemisinin-based combination treatments</p></caption><graphic xlink:href="12879_2017_2876_Fig4_HTML" id="MO4"/></fig>
</p><p id="Par56">DAFH in non-anaemic children were similar for all three treatments [5.7% (95% CI 5.1&#x02013;6.2, <italic>n</italic>&#x02009;=&#x02009;167) versus 5.5% (95% CI 4.9&#x02013;6.1, <italic>n</italic>&#x02009;=&#x02009;155) versus 5.6% (95% CI 5.1&#x02013;6.2, <italic>n</italic>&#x02009;=&#x02009;184) in AL-, AA- and DHP-treated children, respectively, <italic>P</italic>&#x02009;=&#x02009;0.93]. Similarly, mean DAFH in anaemic children were similar for all three treatments [3.2% (95% CI 2.7&#x02013;3.7, <italic>n</italic>&#x02009;=&#x02009;67) versus 3.2% (95% CI 2.7&#x02013;3.8, <italic>n</italic>&#x02009;=&#x02009;79) versus 3.9% (95% CI 3.2&#x02013;4.5, <italic>n</italic>&#x02009;=&#x02009;67) in AL-, AA- and-treated children, respectively, <italic>P</italic>&#x02009;=&#x02009;0.2]. The proportions of children with DAFH in excess of 4% were also similar for all three treatments in non-anaemic [97 of 167 (58%) versus 82 of 155 (53%) versus 100 of 184 children (54%) in AL-, AA- and DHP-treated children, respectively <italic>P</italic>&#x02009;=&#x02009;0.62] and in&#x000a0;anaemic children [16 of 67 (24%) versus 19 of 79 (24%) versus 20 of 67 children (30%) in AL-, AA- and DHP-treated children, respectively <italic>P</italic>&#x02009;=&#x02009;0.66].</p><p id="Par57">Factors associated with DAFH in excess of 4% are shown in Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref>. In a univariate analysis, enrolment body temperature&#x02009;&#x02265;&#x02009;38&#x000b0;C, history of fever at presentation, fever 1&#x000a0;day post-treatment initiation, enrolment haematocrit &#x02265;37%, enrolment parasitaemia &#x0003e;100,000&#x000a0;&#x003bc;L<sup>&#x02212;1</sup>, no gametocytaemia at presentation and within one week post-treatment initiation were significantly associated with DAFH &#x0003e;4%. In a multivariate analysis, history of fever at presentation, fever 1&#x000a0;day post-treatment initiation, enrolment haematocrit &#x02265;37%, and enrolment parasitaemia &#x0003e;100,000&#x000a0;&#x003bc;L<sup>&#x02212;1</sup> were independent predictors of DAFH &#x0003e;4% (Table <xref rid="Tab5" ref-type="table">5</xref>).<table-wrap id="Tab5"><label>Table 5</label><caption><p>Predictors of drug-attributable falls in haematocrit (DAFH) in excess of 4% in &#x0003c;5&#x000a0;year-old children with uncomplicated falciparum malaria following artemisinin-based combination treatments</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>Total no.</th><th>No. with DAFH &#x0003e;4%</th><th>OR (95% CI)</th><th>
<italic>P</italic> value</th><th>AOR (95% CI)</th><th>
<italic>P</italic> value</th></tr></thead><tbody><tr><td colspan="7">Gender</td></tr><tr><td>&#x02003;Female</td><td>323</td><td>152</td><td>1</td><td/><td/><td/></tr><tr><td>&#x02003;Male</td><td>395</td><td>181</td><td>0.8 (0.6&#x02013;1.1)</td><td>0.15</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td colspan="7">Age (month)</td></tr><tr><td>&#x02003;&#x0003e;&#x02009;15</td><td>627</td><td>291</td><td>1</td><td/><td/><td/></tr><tr><td>&#x02003;&#x02264;&#x02009;15</td><td>88</td><td>40</td><td>1.0 (0.6&#x02013;1.5)</td><td>0.96</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td colspan="7">Duration of illness (day)</td></tr><tr><td>&#x02003;&#x02264;&#x02009;2</td><td>235</td><td>125</td><td>1</td><td/><td/><td/></tr><tr><td>&#x02003;&#x0003e;&#x02009;2</td><td>262</td><td>122</td><td>0.8 (0.5&#x02013;1.1)</td><td>0.17</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td colspan="7">Enrolment body temperature (&#x000b0;C)</td></tr><tr><td>&#x02003;&#x0003c;&#x02009;38</td><td>389</td><td>159</td><td>1</td><td/><td>1</td><td/></tr><tr><td>&#x02003;&#x02265;&#x02009;38</td><td>330</td><td>175</td><td>1.6 (1.2&#x02013;2.2)</td><td>0.001</td><td>1.3 (1.0&#x02013;1.8)</td><td>0.09</td></tr><tr><td colspan="7">History of fever at enrolment</td></tr><tr><td>&#x02003;Absent</td><td>109</td><td>26</td><td>1</td><td/><td>1</td><td/></tr><tr><td>&#x02003;Present</td><td>610</td><td>308</td><td>3.3 (2.0&#x02013;5.2)</td><td>&#x0003c; 0.0001</td><td>3.0 (1.8&#x02013;4.9)</td><td>&#x0003c;0.0001</td></tr><tr><td colspan="7">Fever on day 1</td></tr><tr><td>&#x02003;Absent</td><td>611</td><td>267</td><td>1</td><td/><td>1</td><td/></tr><tr><td>&#x02003;Present</td><td>91</td><td>58</td><td>2.3 (1.4&#x02013;3.6)</td><td>0.001</td><td>1.8 (1.1&#x02013;2.9)</td><td>0.02</td></tr><tr><td colspan="7">Haematocrit (%)</td></tr><tr><td>&#x02003;&#x0003c;&#x02009;37</td><td>641</td><td>271</td><td>1</td><td/><td>1</td><td/></tr><tr><td>&#x02003;&#x02265;&#x02009;37</td><td>78</td><td>63</td><td>5.7 (3.2&#x02013;10.3)</td><td>&#x0003c; 0.0001</td><td>5.5 (3.0&#x02013;10.2)</td><td>&#x0003c;0.0001</td></tr><tr><td colspan="7">Parasitaemia (&#x003bc;L<sup>&#x02212;1</sup>)</td></tr><tr><td>&#x02003;&#x02264;&#x02009;100,000</td><td>631</td><td>227</td><td>1</td><td/><td>1</td><td/></tr><tr><td>&#x02003;&#x0003e;&#x02009;100,000</td><td>85</td><td>55</td><td>2.3 (1.5&#x02013;3.8)</td><td>&#x0003c; 0.0001</td><td>2.1 (1.3&#x02013;3.5)</td><td>0.004</td></tr><tr><td colspan="7">Parasitaemia on day 1</td></tr><tr><td>&#x02003;Absent</td><td>288</td><td>133</td><td>1</td><td/><td/><td/></tr><tr><td>&#x02003;Present</td><td>431</td><td>201</td><td>1.0 (0.8&#x02013;1.4)</td><td>0.84</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td colspan="7">Gametocytaemia (D0)</td></tr><tr><td>&#x02003;Present</td><td>31</td><td>7</td><td>1</td><td/><td>1</td><td/></tr><tr><td>&#x02003;Absent</td><td>688</td><td>327</td><td>3.1 (1.3&#x02013;7.3)</td><td>0.01</td><td>1.7 (0.5&#x02013;5.8)</td><td>0.36</td></tr><tr><td colspan="7">Gametocyteamia (within D0&#x02013;7)</td></tr><tr><td>&#x02003;Present</td><td>61</td><td>16</td><td>1</td><td/><td>1</td><td/></tr><tr><td>&#x02003;Absent</td><td>658</td><td>318</td><td>2.6 (1.5&#x02013;4.7)</td><td>0.001</td><td>1.4 (0.6&#x02013;3.3)</td><td>0.44</td></tr><tr><td colspan="7">Parasite clearance time (day)</td></tr><tr><td>&#x02003;&#x02264;&#x02009;2</td><td>563</td><td>259</td><td>1</td><td/><td/><td/></tr><tr><td>&#x02003;&#x0003e;&#x02009;2</td><td>155</td><td>75</td><td>1.1 (0.8&#x02013;1.6)</td><td>0.66</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td colspan="7">Fever clearance time (day)</td></tr><tr><td>&#x02003;&#x02264;&#x02009;2</td><td>455</td><td>223</td><td>1</td><td/><td/><td/></tr><tr><td>&#x02003;&#x0003e;&#x02009;2</td><td>19</td><td>10</td><td>1.2 (0.5&#x02013;2.9)</td><td>0.94</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td colspan="7">Season of enrolment</td></tr><tr><td>&#x02003;Dry (November&#x02013;March)</td><td>43</td><td>16</td><td>1</td><td/><td/><td/></tr><tr><td>&#x02003;Wet (April&#x02013;October)</td><td>676</td><td>318</td><td>1.5 (0.8&#x02013;2.8)</td><td>0.27</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td colspan="7">Drug treatment</td></tr><tr><td>&#x02003;DHP</td><td>251</td><td>120</td><td>1</td><td/><td/><td/></tr><tr><td>&#x02003;AL</td><td>234</td><td>113</td><td>1.0 (0.7&#x02013;1.5)</td><td>0.99</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td>&#x02003;AA</td><td>234</td><td>101</td><td>0.8 (0.6&#x02013;1.2)</td><td>0.35</td><td/><td/></tr></tbody></table><table-wrap-foot><p>
<italic>OR</italic> odd ratio; <italic>AOR</italic> adjusted odd ratio, <italic>CI</italic> confidence interval, <italic>DAFH</italic> drug-attributable fall in haematocrit, <italic>DHP</italic> dihydroartemisinin-piperaquine, <italic>AL</italic> artemether-lumefantrine, <italic>AA</italic> artesunate-amodiaquine</p></table-wrap-foot></table-wrap>
</p><p id="Par58">Of the non-anaemic children who subsequently became anaemic 1&#x000a0;week after start of treatment [EAA], 245 of 298 children (82%) had DAFH &#x0003e;4%. At a DAFH of 4%, 84 of 301 non-anaemic children at presentation (28%) progressed to anaemia within 1&#x000a0;week. At a DAFH of 10%, 121 of 301 non-anaemic children at presentation (40%) progressed to anaemia within 1&#x000a0;week.</p></sec><sec id="Sec18"><title>Kinetics of the disposition of drug-attributable falls in haematocrit</title><p id="Par59">The demographic and other characteristics of the 432 children enrolled in kinetics of the disposition of DAFH study (<italic>n</italic>&#x02009;=&#x02009;148 for AL, <italic>n</italic>&#x02009;=&#x02009;138 for AA and <italic>n</italic>&#x02009;=&#x02009;146 for DHP) are shown in Table&#x000a0;<xref rid="Tab6" ref-type="table">6</xref>. Overall, there was a monoexponential decline of the deficits in DAFH with an estimated mean half-time (t<sub>&#x000bd;el</sub>) of 2.2&#x000a0;days (95% CI 1.9&#x02013;2.6) (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5a</xref>). Estimated t<sub>&#x000bd;el</sub> was significantly higher in children treated with DHP compared to AA and AL [2.8&#x000a0;days (95% CI 2.1&#x02013;3.5, <italic>n</italic>&#x02009;=&#x02009;146) versus 1.6&#x000a0;days (95% CI 1.3&#x02013;2, <italic>n</italic>&#x02009;=&#x02009;138) versus 2.2&#x000a0;days (95% CI 1.7&#x02013;2.8, <italic>n</italic>&#x02009;=&#x02009;148), respectively <italic>P</italic>&#x02009;=&#x02009;0.01] but it was similar between AA and AL (<italic>P</italic>&#x02009;=&#x02009;0.27). Estimated t<sub>&#x000bd;el</sub> was also significantly higher in children who were non-anaemic compared to anaemic children at presentation [2.7&#x000a0;days (95% CI 2.2&#x02013;3.1, <italic>n</italic>&#x02009;=&#x02009;318) versus 1.1&#x000a0;days (95% CI 0.9&#x02013;1.2, <italic>n</italic>&#x02009;=&#x02009;114) <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001] (Fig. <xref rid="Fig5" ref-type="fig">5b</xref>).<table-wrap id="Tab6"><label>Table 6</label><caption><p>Demographic and clinical characteristics of &#x0003c;5&#x000a0;years old children with uncomplicated falciparum malaria enrolled in study of the kinetics of the disposition of drug-attributable falls in haematocrit following artemisinin-based combination treatments</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="4">Treatment</th><th rowspan="2">
<italic>P</italic> value</th></tr><tr><th/><th>AA (<italic>n</italic>&#x02009;=&#x02009;138)</th><th>AL (<italic>n</italic>&#x02009;=&#x02009;148)</th><th>DHP (<italic>n</italic>&#x02009;=&#x02009;146)</th><th>ALL (<italic>n</italic>&#x02009;=&#x02009;432)</th></tr></thead><tbody><tr><td>Male/Female</td><td>78/60</td><td>74/74</td><td>82/64</td><td>234/198</td><td>0.45</td></tr><tr><td colspan="6">Age (month)</td></tr><tr><td>&#x02003;Mean (95% CI)</td><td>38.4 (35.6&#x02013;41.2)</td><td>41 (38.5&#x02013;43.6)</td><td>36.5 (33.6&#x02013;39.2)</td><td>38.6 (37.1&#x02013;40.2)</td><td>0.06</td></tr><tr><td>&#x02003;Age&#x02009;&#x02264;&#x02009;24 [%]</td><td>36 [26]</td><td>27 [18]</td><td>53 [36]</td><td>116 [27]</td><td>0.002</td></tr><tr><td colspan="6">Duration of illness (day)</td></tr><tr><td>&#x02003;Mean (95% CI)</td><td>3.6 (3.1&#x02013;4.1)</td><td>3.6 (3.1&#x02013;4.1)</td><td>3.4 (2.9&#x02013;3.9)</td><td>3.5 (3.2&#x02013;3.8)</td><td>0.79</td></tr><tr><td colspan="6">Temperature (&#x000b0;C)</td></tr><tr><td>&#x02003;Mean (95% CI)</td><td>37.9 (37.7&#x02013;38.1)</td><td>37.9 (37.5&#x02013;38.2)</td><td>37.8 (37.4&#x02013;38.2)</td><td>37.9 (37.6&#x02013;38.1)</td><td>0.76</td></tr><tr><td colspan="6">No. with temperature</td></tr><tr><td>&#x02003;&#x0003e;&#x02009;37.4&#x000a0;&#x000b0;C [%]</td><td>94 [68]</td><td>104 [70]</td><td>95 [65]</td><td>293 [68]</td><td>0.63</td></tr><tr><td>&#x02003;&#x0003e;&#x02009;40&#x000a0;&#x000b0;C [%]</td><td>9 [6.5]</td><td>4 [3]</td><td>7 [5]</td><td>20 [5]</td><td>0.29</td></tr><tr><td colspan="6">Haematocrit (%)</td></tr><tr><td>&#x02003;Mean (95% CI)</td><td>31.8 (31&#x02013;32.6)</td><td>31.9 (31.2&#x02013;32.7)</td><td>32.3 (31.5&#x02013;33)</td><td>32 (31.6&#x02013;33.4)</td><td>0.67</td></tr><tr><td>&#x02003;No. with haematocrit &#x0003c;30% [%]</td><td>44 [32]</td><td>40 [27]</td><td>34 [23]</td><td>114 [26]</td><td>0.54</td></tr><tr><td colspan="6">Parasitaemia (&#x003bc;L<sup>&#x02212;1</sup>)</td></tr><tr><td>&#x02003;Geometric mean</td><td>17,737</td><td>22,202</td><td>20,767</td><td>20,210</td><td>0.36</td></tr><tr><td>&#x02003;Range</td><td>2000&#x02013;200,000</td><td>2004&#x02013;200,000</td><td>2003&#x02013;200,000</td><td>2000&#x02013;200,000</td><td/></tr><tr><td colspan="6">No with parasitaemia</td></tr><tr><td>&#x02003;&#x0003e;&#x02009;100,000 [%]</td><td>90 [65]</td><td>102 [69]</td><td>99 [68]</td><td>291 [67]</td><td>0.84</td></tr><tr><td>&#x02003;Gametocyte carriage [%]</td><td>12 [8.7]</td><td>7 [4.7]</td><td>11 [7.5]</td><td>30 [6.9]</td><td>0.38</td></tr><tr><td colspan="6">Fever clearance time (day)</td></tr><tr><td>&#x02003;Mean (95% CI)</td><td>1.1 (1.1&#x02013;1.2)</td><td>1.3 (1.2&#x02013;1.4)</td><td>1.2 (1.1&#x02013;1.3)</td><td>1.2 (1.2&#x02013;1.3)</td><td>0.07</td></tr><tr><td colspan="6">Parasite positivity</td></tr><tr><td>&#x02003;On day 1 [%]</td><td>75 [54]</td><td>98 [66]</td><td>81 [55]</td><td>254 [59]</td><td>0.07</td></tr><tr><td>&#x02003;On day 3 [%]</td><td>2 [1.4]</td><td>3 [2]</td><td>2 [1.4]</td><td>9 [2.1]</td><td>0.66</td></tr><tr><td colspan="6">Parasite clearance time (day)</td></tr><tr><td>&#x02003;Mean (95% CI)</td><td>1.8 (1.6&#x02013;1.9)</td><td>1.9 (1.8&#x02013;2)</td><td>1.7 (1.6&#x02013;1.8)</td><td>1.8 (1.7&#x02013;1.9)</td><td>0.054</td></tr></tbody></table><table-wrap-foot><p>
<italic>AA</italic> artesunate-amodiaquine, <italic>AL</italic> artemether-lumefantrine, <italic>DHP</italic> dihydroartemisinin-piperaquine, <italic>CI</italic> confidence interval</p></table-wrap-foot></table-wrap>
<fig id="Fig5"><label>Fig. 5</label><caption><p>Semilog plots of deficit in haematocrit from baseline versus time (<bold>a</bold>) in all children (black line), anaemic (green line) and non-anaemic children (blue line) and (<bold>b</bold>) in children treated with artemether lumefantrine (red line), artesunate-amodiaquine (green line) or dihydroartemisinin-piperaquine (blue line)</p></caption><graphic xlink:href="12879_2017_2876_Fig5_HTML" id="MO5"/></fig>
</p><p id="Par60">Overall, estimated mean estimated AUC<sub>(DAFH)</sub> was 56.3%.day (95% CI 48.5&#x02013;64.2). Estimated mean AUC<sub>DAFH</sub> was significantly higher in children treated with DHP compared to AA and AL [67%.day (95% CI 57.4&#x02013;82.6, <italic>n</italic>&#x02009;=&#x02009;146) versus 41.7%.day (95% CI 32.5&#x02013;50.8, <italic>n</italic>&#x02009;=&#x02009;138) versus 59.5%.day (95% CI 44.7&#x02013;74.3, <italic>n</italic>&#x02009;=&#x02009;148), respectively <italic>P</italic>&#x02009;=&#x02009;0.03] but it was similar between AA and AL (<italic>P</italic>&#x02009;=&#x02009;0.16). Estimated mean AUC<sub>DAFH</sub> was also significantly higher in children who were non-anaemic compared to anaemic children at presentation [66.1%.day (95% CI 57&#x02013;75.2, <italic>n</italic>&#x02009;=&#x02009;317) versus 29.3%.day (95% CI 14.5&#x02013;44.1, <italic>n</italic>&#x02009;=&#x02009;114) <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001].</p></sec><sec id="Sec19"><title>Relationship between area under curve of the plot of deficit in drug-attributable falls in haematocrit and value of drug-attributable falls in haematocrit</title><p id="Par61">The relationship between AUC<sub>(DAFH)</sub> and the value of DAFH was evaluated in 432 children. The mean of the ratio of AUC<sub>(DAFH)</sub>: value of DAFH was 8.8 (95% CI 7.4&#x02013;10.3). There was a significantly positive correlation between AUC<sub>(DAFH)</sub> and value of DAFH (<italic>r</italic>&#x02009;=&#x02009;0.47, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001). Bland-Altman plots of AUC<sub>(DAFH)</sub> and multiples of values of DAFH are shown in Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>. The limits of agreement between AUC<sub>(DAFH)</sub> and 9 or 10 multiples of value of DAFH were narrow. At 9 and 10 multiples of value of DAFH, the limits of agreement were &#x02212;142.1 &#x02013; 148.6% and &#x02212;147.4 &#x02013; 142.1%, respectively. The bias at multiples of 9 or 10 value of DAFH was statistically insignificant (<italic>P</italic>&#x02009;=&#x02009;0.36 and 0.46, respectively) indicating that AUC<sub>(DAFH)</sub> and 9 or 10 multiples of value of DAFH can be used interchangeably in the same patient. However, there was a statistically significant bias at 8 multiples of value of DAFH (<italic>P</italic>&#x02009;=&#x02009;0.01).<fig id="Fig6"><label>Fig. 6</label><caption><p>Bland-Altman plots of area under curve of drug-attributable fall in haematocrit (AUC<sub>(DAFH)</sub>) and multiples [8 (<bold>a</bold>), 9 (<bold>b</bold>) and 10 (<bold>c</bold>)] of values of drug-attributable falls in haematocrit. Biases were 9.18, 3.27 and &#x02212;2.63 for plots A, B and C; <italic>P</italic>&#x02009;=&#x02009;0.01, 0.36 and 0.46, respectively. The mean values &#x000b1;1.96 standard deviation (SD) of the differences are shown</p></caption><graphic xlink:href="12879_2017_2876_Fig6_HTML" id="MO6"/></fig>
</p></sec></sec><sec id="Sec20"><title>Discussion</title><p id="Par62">In this study, we evaluated prospectively in young malarious children, the factors contributing to: anaemia at presentation, anaemia one week after starting treatment in children who were not anaemic at presentation, the burden of anaemia imposed by a single episode of malaria, the falls and the duration of falls in haematocrit attributable to three ACTs. Our results showed: anaemia is common at presentation and in the one week following initiation of treatment; the burden of anaemia after a single episode of infection is high; and drug related falls in haematocrit are significantly more common and more severe in children who were not anaemic at presentation compared with those who were anaemic at presentation.</p><p id="Par63">Compared with factors contributing to anaemia during the early period of adoption of ACTs as first-line antimalarials in the study areas [<xref ref-type="bibr" rid="CR8">8</xref>], the factors contributing to anaemia ten years after adoption as first-line treatments appeared to have been considerably modified as shown in the results of the present study. The significant modifications include: reduction in age band susceptible to malarial anaemia at presentation from children 6&#x02013;59&#x000a0;months to children 6&#x02013;15&#x000a0;months and relatively low gametocyte carriage at presentation or following treatment. However, the prevalence of anaemia at presentation and the burden of anaemia following a single episode of infection appeared to have been little affected. The low gametocyte carriage ten years following adoption as first-line antimalarials can be attributable to rapid clearance of asexual parasitaemia [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>] and alteration in gametocyte sex ratios [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>] which can produce a female bias sex ratio that is less infective to mosquitoes [<xref ref-type="bibr" rid="CR34">34</xref>]. It has also been postulated that ACTs can mobilize immature gametocytes from bone marrow to peripheral blood where they can be rapidly eliminated by components of ACTs [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. The latter can also prevent development of immature gametocytes which are non-infective to mosquitoes to mature gametocyte which are infective to mosquitoes [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. This is particularly important because all components of ACTs can kill immature gametocytes. It is not apparent from the results of the present study why a low asexual parasitaemia is a predictor of anaemia at presentation. This finding is paradoxical.</p><p id="Par64">Progression to anaemia within one week of treatment initiation in a half of the children who were not anaemic at presentation can be clearly attributable to relatively high DAFH values with all three treatments. These children differ significantly from anaemic children at presentation in whom DAFH values were relatively low and who did not have a worsening of their anaemia in the one week following treatment initiation (Fig. <xref rid="Fig5" ref-type="fig">5</xref>). This finding in anaemic children suggests considerable degree of &#x0201c;haematocrit conservation&#x0201d; [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. Taking together, this would suggest the three ACTs may prevent further falls in haematocrit in anaemic children at presentation and in half of non-anaemic children at presentation.</p><p id="Par65">The burden of anaemia imposed by a single episode of infection was relatively high and it occurred in two-third of the young malarious children. In these children, repeated attacks of acute infections within a short time frame can be expected to lead to development of anaemia [<xref ref-type="bibr" rid="CR16">16</xref>]. Expectedly, anaemia and gametocytaemia at presentation predicted MAFH &#x0003e;4%. Indeed the risk of MAFH &#x0003e;4% was approximately nine and a half fold higher in anaemic compared to non-anaemic children at presentation (Table <xref rid="Tab4" ref-type="table">4</xref>). Taking together with factors predicting anaemia at presentation, it would appear that by reducing the age band susceptible to malaria at presentation from 6 to 59&#x000a0;months to 6&#x02013;15&#x000a0;months, ACTs have, during the ten years of adoption as first-line treatments, not reduced the burden of anaemia imposed by a single episode of an apparently uncomplicated infection. We have no ready explanation for a presenting parasitaemia &#x02264;50,000&#x000a0;&#x003bc;L<sup>&#x02212;1</sup> being a predictor of MAFH in excess of 4%.</p><p id="Par66">The early-appearing anaemia in 50% of non-anaemic children was clearly attributable to DAFH in excess of 4% (see above, paragraph&#x000a0;3). Therefore, all of the predictors of DAFH in excess of 4% were not unexpected (Table <xref rid="Tab5" ref-type="table">5</xref>). However, there is no ready explanation from the results presented for temperature in excess of 37.9&#x000b0;C being a predictor of DAFH in excess of 4%. In this context, there is need to justify the use of DAFH &#x0003e;4% as cut off for predictors of DAFH. Firstly, this cut off has been used in a previous study [<xref ref-type="bibr" rid="CR16">16</xref>]. Second, a&#x02009;&#x02265;&#x02009;5% (5&#x000a0;units) fall in haematocrit from baseline is unlikely to be a random effect and likely to represent a significant fall from baseline in a manner similar to using 95% confidence interval in a two-way analysis of variance [<xref ref-type="bibr" rid="CR30">30</xref>].</p><p id="Par67">An important question arising from the present study is whether there are differences in the recovery from anaemia attributable to infections (pre-treatment anaemia) and the anaemia which follows treatment of the infections in patients who were not previously anaemic at presentation (early-appearing anaemia). Overall, it would appear there are significant differences as evidenced by the significantly longer anaemia recovery time in children with anaemia primarily due to the infections compared to the anaemia following treatment of the infections. Additionally, pre-treatment anaemia is primarily due to interaction(s) between host and the parasites while the anaemia following treatment is due to interaction(s) between host, parasite and the drug. A striking feature of all non-anaemic children pre-treatment who progressed to early-appearing anaemia were: most had pre-treatment haematocrit close to the lower threshold of normal and the critical falls in haematocrit at which all progressed to anemia was a drug-attributable fall in excess of 10% (Fig. <xref rid="Fig4" ref-type="fig">4</xref>). Perhaps determining threshold for progression of all those developing early appearing anaemia should form routine part of the clinical evaluation of drug-attributable falls in haematocrit following different drug regimens. The pre-treatment haematocrit threshold in the cohort of children with normal haematocrit at presentation appears to be a haematocrit of 40%.</p><p id="Par68">The ratio of the estimated AUC<sub>(DAFH)</sub> to value of DAFH was approximately nine folds. This ratio represents the relationship of a pharmacokinetic estimate to a pharmacodynamic estimate&#x000a0;- two methods of measuring DAFH in the same patients employed in the present study. An intriguing feature of the ratio is: it is somewhat similar to the number of half-times required for &#x0003e;99.9% completion of a pharmacokinetic process in a rudimentary one-compartment pharmacokinetic model. A somewhat more intriguing finding is their insignificant agreement when 9 or 10 multiples of value of DAFH and AUC<sub>(DAFH)</sub> were subjected to Bland-Altman analyses. The analyses indicate both measurements can be used interchangeably in the same patients despite the difference in their units of measurement. The difference in units of measurement would suggest some further application of Bland-Altman analysis when applied to establishing agreement between pharmacokinetic and pharmacodynamic processes in clinical drug studies.</p><p id="Par69">The main limitation of the present study is not quantifying once-infected red blood cells. Quantification of once-infected red blood cells would have enabled the study to distinguish between non-anaemic children at presentation who progressed to early-appearing anaemia from those who did not. Another limitation is that the study did not evaluate the contribution of the background causes of anaemia, to the factors contributing to anaemia pre- and post-treatment initiation.</p></sec><sec id="Sec21"><title>Conclusions</title><p id="Par70">In conclusion, after ten years of adopting of ACTs as first-line antimalarials in Nigeria, anaemia is common pre-and early post-treatment, anaemia burden of a single infection is relatively high, and drug-attributable falls in haematocrit &#x0003e;4% is common and significantly lower in anaemic compared to non-anaemic malarious children.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>%</term><def><p id="Par6">Percent</p></def></def-item><def-item><term><sup>o</sup>C</term><def><p id="Par7">Degree celsius</p></def></def-item><def-item><term>AA</term><def><p id="Par8">Artesunate-amodiaquine</p></def></def-item><def-item><term>ACTs</term><def><p id="Par9">Artemisinin-based combination treatments</p></def></def-item><def-item><term>AL</term><def><p id="Par10">Artemether-lumefantrine</p></def></def-item><def-item><term>AOR</term><def><p id="Par11">Adjusted odds ratio</p></def></def-item><def-item><term>AUC</term><def><p id="Par12">Area under curve</p></def></def-item><def-item><term>AUC<sub>(DAFH)</sub></term><def><p id="Par13">Area under curve of drug-attributable falls in haematocrit versus time</p></def></def-item><def-item><term>CI</term><def><p id="Par14">Confidence interval</p></def></def-item><def-item><term>d</term><def><p id="Par15">Day</p></def></def-item><def-item><term>DAFH</term><def><p id="Par16">Drug-attributable falls in haematocrit</p></def></def-item><def-item><term>DHP</term><def><p id="Par17">Dihydroartemisinin-piperaquine</p></def></def-item><def-item><term>EAA</term><def><p id="Par18">Early-appearing anaemia</p></def></def-item><def-item><term>g</term><def><p id="Par19">Gram</p></def></def-item><def-item><term>kg</term><def><p id="Par20">Kilogram</p></def></def-item><def-item><term>L</term><def><p id="Par21">Litre</p></def></def-item><def-item><term>M/F</term><def><p id="Par22">Male/female</p></def></def-item><def-item><term>MAFH</term><def><p id="Par23">Malaria-attributable fall in haematocrit</p></def></def-item><def-item><term>mg</term><def><p id="Par24">Milligram</p></def></def-item><def-item><term>OR</term><def><p id="Par25">Odds ratio</p></def></def-item><def-item><term>t<sub>1/2</sub></term><def><p id="Par26">Half-time</p></def></def-item><def-item><term>TMAFH</term><def><p id="Par27">Total malaria-attributable fall in haematocrit</p></def></def-item><def-item><term>&#x003bc;L</term><def><p id="Par28">Microliter</p></def></def-item></def-list></glossary><ack><title>Acknowledgements</title><p>We are grateful to the parents/guardians and the children who participated in the study.</p><sec id="FPar1"><title>Funding</title><p id="Par71">The therapeutic efficacy study from which the data were derived received financial support from Global Fund for AIDS, Tuberculosis and Malaria, United States Presidential Malaria Initiative (PMI), and Malaria Consortium Grants to The Federal Ministry of Health, Abuja, through Drug Therapeutic Efficacy Testing in Nigeria. Logistic support was provided by The Government of the States where the sites are located.</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p id="Par72">The dataset supporting the findings of this article are available from the corresponding author upon request.</p></sec></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>AS led the design, conduct, data analysis and manuscript preparation. BF was involved in data analysis; KA in data collection, analysis and manuscript preparation; OAW in data analysis, CA in data management; FF, JE, NJ, JA, RW, GN, OM, GE, NE, WAO, FU in data collection; AIA, EOA, GOG, OAF, CTH, SO in data analysis. CA, FF, JE, NJ, JA, RW, GN, OM, GE, WAO and FU made substantial contributions to the conception, design and conduct of the study. AS, FF, JE, NJ, JA, RW, OM and GE were Principal Investigators at the sentinel sites. All authors read, contributed and approved the final draft of the manuscript.</p></notes><notes notes-type="COI-statement"><sec id="FPar3"><title>Ethics approval and consent to participate</title><p id="Par73">The study protocol was approved by National Health Research Ethics Committee, Abuja, Nigeria. NHREC/01/01/2007&#x02013;28/10/2013 (29 October 2013), NHREC/01/01/2007&#x02013;22/10/2014 (30 October 2014). Written informed consents were obtained from parents/guardians of the children.</p></sec><sec id="FPar4"><title>Consent for publication</title><p id="Par74">Not applicable</p></sec><sec id="FPar5"><title>Competing interests</title><p id="Par75">The authors declare they have no competing interests.</p></sec><sec id="FPar6"><title>Publisher&#x02019;s Note</title><p id="Par76">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bosman</surname><given-names>A</given-names></name><name><surname>Mendis</surname><given-names>KNA</given-names></name></person-group><article-title>Major transition in malaria treatment: the adoption and deployment of artemisinin-based combination therapies</article-title><source>Am J Trop Med Hyg</source><year>2007</year><volume>66</volume><issue>Suppl 6</issue><fpage>193</fpage><lpage>197</lpage></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><source>World malaria report 2015</source><year>2015</year><publisher-loc>Geneva</publisher-loc><publisher-name>WHO</publisher-name></element-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">World Health Organization. Antimalarial Drug Combination Therapy. Report of a WHO Technical Consultation. Geneva: World Health Organization. 2001. WHO/CDS/RBM/2001.35.</mixed-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carrara</surname><given-names>VI</given-names></name><name><surname>Zwang</surname><given-names>J</given-names></name><name><surname>Ashley</surname><given-names>EA</given-names></name><name><surname>Price</surname><given-names>RN</given-names></name><name><surname>Stepniewka</surname><given-names>K</given-names></name><name><surname>Marion</surname><given-names>B</given-names></name><name><surname>Brockman</surname><given-names>A</given-names></name><name><surname>Anderson</surname><given-names>T</given-names></name><name><surname>McGready</surname><given-names>R</given-names></name><name><surname>Phaiphun</surname><given-names>L</given-names></name><name><surname>Stephane</surname><given-names>P</given-names></name><name><surname>van Vugt</surname><given-names>M</given-names></name><name><surname>Hutagalung</surname><given-names>R</given-names></name><name><surname>Lwin</surname><given-names>KM</given-names></name><name><surname>Phyo</surname><given-names>AP</given-names></name><name><surname>Piyanuch</surname><given-names>P</given-names></name><name><surname>Imwong</surname><given-names>M</given-names></name><name><surname>Pukrittayakamee</surname><given-names>S</given-names></name><name><surname>Singhasivanon</surname><given-names>P</given-names></name><name><surname>White</surname><given-names>NJ</given-names></name><name><surname>Nosten</surname><given-names>F</given-names></name></person-group><article-title>Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment</article-title><source>PLoS One</source><year>2009</year><volume>4</volume><fpage>e4551</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0004551</pub-id><pub-id pub-id-type="pmid">19234601</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phyo</surname><given-names>AP</given-names></name><name><surname>Ashley</surname><given-names>EA</given-names></name><name><surname>Anderson</surname><given-names>TJC</given-names></name><name><surname>Bozdech</surname><given-names>Z</given-names></name><name><surname>Carrara</surname><given-names>VI</given-names></name><name><surname>Sriprawat</surname><given-names>K</given-names></name><name><surname>Nair</surname><given-names>S</given-names></name><name><surname>White</surname><given-names>MM</given-names></name><name><surname>Dziekan</surname><given-names>J</given-names></name><name><surname>Ling</surname><given-names>C</given-names></name><name><surname>Proux</surname><given-names>S</given-names></name><name><surname>Konghahong</surname><given-names>K</given-names></name><name><surname>Jeeyapant</surname><given-names>A</given-names></name><name><surname>Woodrow</surname><given-names>CJ</given-names></name><name><surname>Imwong</surname><given-names>M</given-names></name><name><surname>McGready</surname><given-names>R</given-names></name><name><surname>Lwin</surname><given-names>KM</given-names></name><name><surname>Day</surname><given-names>NPJ</given-names></name><name><surname>White</surname><given-names>NJ</given-names></name><name><surname>Nosten</surname><given-names>F</given-names></name></person-group><article-title>Declining efficacy of artemisinin combination therapy against <italic>P. falciparum</italic> malaria on the Thai-Myanmar border (2003-2013): the role of parasite genetic factors</article-title><source>Clin Infect Dis</source><year>2016</year><volume>63</volume><fpage>784</fpage><lpage>791</lpage><pub-id pub-id-type="doi">10.1093/cid/ciw388</pub-id><pub-id pub-id-type="pmid">27313266</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Federal Ministry of Health</collab></person-group><source>National Antimalaria Treatment Guideline</source><year>2005</year><publisher-loc>Abuja, Nigeria</publisher-loc><publisher-name>Federal Ministry of Health</publisher-name></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nkuo-Akenji</surname><given-names>TK</given-names></name><name><surname>Chi</surname><given-names>PC</given-names></name><name><surname>Cho</surname><given-names>JF</given-names></name><name><surname>Ndamukong</surname><given-names>KK</given-names></name><name><surname>Sumbele</surname><given-names>I</given-names></name></person-group><article-title>Malaria and helminth co-infection in children living in a malaria endemic setting of Mount Cameroon and predictors of anemia</article-title><source>J Parasitol</source><year>2006</year><volume>92</volume><fpage>1191</fpage><lpage>1195</lpage><pub-id pub-id-type="doi">10.1645/GE-895R.1</pub-id><pub-id pub-id-type="pmid">17304793</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sowunmi</surname><given-names>A</given-names></name><name><surname>Gbotosho</surname><given-names>GO</given-names></name><name><surname>Happi</surname><given-names>CT</given-names></name><name><surname>Fateye</surname><given-names>B</given-names></name></person-group><article-title>Factors contributing to anaemia after uncomplicated <italic>Plasmodium falciparum</italic> malaria in children</article-title><source>Acta Trop</source><year>2010</year><volume>113</volume><fpage>155</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1016/j.actatropica.2009.10.011</pub-id><pub-id pub-id-type="pmid">19874795</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sumbele</surname><given-names>IUN</given-names></name><name><surname>Samje</surname><given-names>M</given-names></name><name><surname>Nkuo-Akenji</surname><given-names>TA</given-names></name></person-group><article-title>Longitudinal study on anaemia in children with <italic>Plasmodium falciparum</italic> infection in the Mount Cameroon region: prevalence, risk factors and perceptions by caregivers</article-title><source>BioMed Central of Infectious Diseases</source><year>2013</year><volume>13</volume><fpage>123</fpage><pub-id pub-id-type="doi">10.1186/1471-2334-13-123</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Price</surname><given-names>RC</given-names></name><name><surname>Simpson</surname><given-names>JA</given-names></name><name><surname>Nosten</surname><given-names>F</given-names></name><name><surname>Luxemberger</surname><given-names>C</given-names></name><name><surname>Hkirjaroen</surname><given-names>L</given-names></name><name><surname>ter Kuile</surname><given-names>F</given-names></name><name><surname>Chongsuphajaisiddhi</surname><given-names>T</given-names></name><name><surname>White</surname><given-names>NJ</given-names></name></person-group><article-title>Factors contributing to anemia after uncomplicated falciparum malaria</article-title><source>Am J Trop Med Hyg</source><year>2001</year><volume>65</volume><fpage>614</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.2001.65.614</pub-id><pub-id pub-id-type="pmid">11716124</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dondorp</surname><given-names>AM</given-names></name><name><surname>Angus</surname><given-names>BJ</given-names></name><name><surname>Chotivanich</surname><given-names>K</given-names></name><name><surname>Silamut</surname><given-names>K</given-names></name><name><surname>Ruangveerayuth</surname><given-names>R</given-names></name><name><surname>Hardeman</surname><given-names>MR</given-names></name><name><surname>Kager</surname><given-names>PA</given-names></name><name><surname>Vreeken</surname><given-names>J</given-names></name><name><surname>White</surname><given-names>NJ</given-names></name></person-group><article-title>Red blood cell deformability as a predictor of anemia in severe falciparum malaria</article-title><source>Am J Trop Med Hyg</source><year>1999</year><volume>60</volume><fpage>733</fpage><lpage>737</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.1999.60.733</pub-id><pub-id pub-id-type="pmid">10344643</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Safeukui</surname><given-names>I</given-names></name><name><surname>Correas</surname><given-names>JM</given-names></name><name><surname>Brousse</surname><given-names>V</given-names></name><name><surname>Hirt</surname><given-names>D</given-names></name><name><surname>Deplaine</surname><given-names>G</given-names></name><name><surname>Mul&#x000e9;</surname><given-names>S</given-names></name><name><surname>Lesurtel</surname><given-names>M</given-names></name><name><surname>Goasguen</surname><given-names>N</given-names></name><name><surname>Sauvanet</surname><given-names>A</given-names></name><name><surname>Couvelard</surname><given-names>A</given-names></name><name><surname>Kerneis</surname><given-names>S</given-names></name><name><surname>Khun</surname><given-names>H</given-names></name><name><surname>Vigan-Womas</surname><given-names>I</given-names></name><name><surname>Ottone</surname><given-names>C</given-names></name><name><surname>Molina</surname><given-names>TJ</given-names></name><name><surname>Tr&#x000e9;luyer</surname><given-names>JM</given-names></name><name><surname>Mercereau-Puijalon</surname><given-names>O</given-names></name><name><surname>Milon</surname><given-names>G</given-names></name><name><surname>David</surname><given-names>PH</given-names></name><name><surname>Buffet</surname><given-names>PA</given-names></name></person-group><article-title>Retention of <italic>Plasmodium falciparum</italic> ring-infected erythrocytes in the slow, open microcirculation of the human spleen</article-title><source>Blood</source><year>2008</year><volume>112</volume><fpage>2520</fpage><lpage>2528</lpage><pub-id pub-id-type="doi">10.1182/blood-2008-03-146779</pub-id><pub-id pub-id-type="pmid">18579796</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buffet</surname><given-names>PA</given-names></name><name><surname>Safeukui</surname><given-names>I</given-names></name><name><surname>Deplaine</surname><given-names>G</given-names></name><name><surname>Brousse</surname><given-names>V</given-names></name><name><surname>Prendki</surname><given-names>V</given-names></name><name><surname>Thellier</surname><given-names>M</given-names></name><name><surname>Turner</surname><given-names>GD</given-names></name><name><surname>Mercereau-Puijalon</surname><given-names>O</given-names></name></person-group><article-title>The pathogenesis of <italic>Plasmodium falciparum</italic> malaria in humans: insights from splenic physiology</article-title><source>Blood</source><year>2011</year><volume>117</volume><fpage>381</fpage><lpage>392</lpage><pub-id pub-id-type="doi">10.1182/blood-2010-04-202911</pub-id><pub-id pub-id-type="pmid">20852127</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ou&#x000e9;draogo</surname><given-names>HZ</given-names></name><name><surname>Zeba</surname><given-names>A</given-names></name><name><surname>Dramaix-Wilmet</surname><given-names>M</given-names></name><name><surname>Donnen</surname><given-names>P</given-names></name></person-group><article-title>Moderate to severe anaemia due to afebrile <italic>Plasmodium falciparum</italic> infections in children aged 6- 23 months from rural district of Kongoussi, Burkina Faso</article-title><source>J Trop Pediatr</source><year>2008</year><volume>54</volume><fpage>395</fpage><lpage>400</lpage><pub-id pub-id-type="doi">10.1093/tropej/fmn049</pub-id><pub-id pub-id-type="pmid">18599531</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Njua-Yafi</surname><given-names>C</given-names></name><name><surname>Achidi</surname><given-names>EA</given-names></name><name><surname>Anchang-Kimbi</surname><given-names>JK</given-names></name><name><surname>Apinjoh</surname><given-names>TO</given-names></name><name><surname>Mugri</surname><given-names>RN</given-names></name><name><surname>Chi</surname><given-names>HF</given-names></name><name><surname>Tata</surname><given-names>RB</given-names></name><name><surname>Njumkeng</surname><given-names>C</given-names></name><name><surname>Nkock</surname><given-names>EN</given-names></name><name><surname>Nkuo-Akenji</surname><given-names>T</given-names></name></person-group><article-title>Malaria, helminths, co-infection and anaemia in a cohort of children from Mutengene, south western Cameroon</article-title><source>Malar J</source><year>2016</year><volume>15</volume><fpage>69</fpage><pub-id pub-id-type="doi">10.1186/s12936-016-1111-2</pub-id><pub-id pub-id-type="pmid">26852392</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sowunmi</surname><given-names>A</given-names></name><name><surname>Balogun</surname><given-names>ST</given-names></name><name><surname>Gbotosho</surname><given-names>GO</given-names></name><name><surname>Happi</surname><given-names>CT</given-names></name></person-group><article-title>Effects of amodiaquine, artesunate, and artesunate-amodiaquine on <italic>Plasmodium falciparum</italic> malaria-associated anaemia in children</article-title><source>Acta Trop</source><year>2009</year><volume>109</volume><fpage>55</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/j.actatropica.2008.09.022</pub-id><pub-id pub-id-type="pmid">18992209</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oguche</surname><given-names>S</given-names></name><name><surname>Okafor</surname><given-names>HU</given-names></name><name><surname>Watila</surname><given-names>I</given-names></name><name><surname>Meremikwu</surname><given-names>M</given-names></name><name><surname>Agomo</surname><given-names>P</given-names></name><name><surname>Ogala</surname><given-names>W</given-names></name><name><surname>Agomo</surname><given-names>C</given-names></name><name><surname>Ntadom</surname><given-names>G</given-names></name><name><surname>Banjo</surname><given-names>O</given-names></name><name><surname>Okuboyejo</surname><given-names>T</given-names></name><name><surname>Ogunrinde</surname><given-names>G</given-names></name><name><surname>Odey</surname><given-names>F</given-names></name><name><surname>Aina</surname><given-names>O</given-names></name><name><surname>Sofola</surname><given-names>T</given-names></name><name><surname>Sowunmi</surname><given-names>A</given-names></name></person-group><article-title>Efficacy of artemisinin-based combination treatments of uncomplicated falciparum malaria in under-five year-old Nigerian children</article-title><source>Am J Trop Med Hyg</source><year>2014</year><volume>91</volume><fpage>925</fpage><lpage>935</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.13-0248</pub-id><pub-id pub-id-type="pmid">25246693</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="other">World Health Organization. Severe falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene 2000; 94 Supp1: 1&#x02013;90.</mixed-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><article-title>Severe malaria</article-title><source>Trop Med Int Health</source><year>2014</year><volume>19</volume><issue>Suppl 1</issue><fpage>7</fpage><lpage>131</lpage><pub-id pub-id-type="pmid">25214480</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sowunmi</surname><given-names>A</given-names></name><name><surname>Akano</surname><given-names>K</given-names></name><name><surname>Ayede</surname><given-names>AI</given-names></name><name><surname>Ntadom</surname><given-names>G</given-names></name><name><surname>Aderoyeje</surname><given-names>T</given-names></name><name><surname>Adewoye</surname><given-names>EO</given-names></name><name><surname>Fatunmbi</surname><given-names>B</given-names></name></person-group><article-title>Clinical illness and outcomes in Nigerian children with late-appearing anaemia after artemisinin-based combination treatments of uncomplicated falciparum malaria</article-title><source>BMC Infect Dis</source><year>2016</year><volume>16</volume><fpage>240</fpage><pub-id pub-id-type="doi">10.1186/s12879-016-1565-4</pub-id><pub-id pub-id-type="pmid">27246468</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="other">World Health Organization: Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. Geneva: world health Organization 2003.</mixed-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sowunmi</surname><given-names>A</given-names></name><name><surname>Akano</surname><given-names>K</given-names></name><name><surname>Ayede</surname><given-names>AI</given-names></name><name><surname>Ntadom</surname><given-names>G</given-names></name><name><surname>Adewoye</surname><given-names>EO</given-names></name><name><surname>Fatunmbi</surname><given-names>B</given-names></name><name><surname>Aderoyeje</surname><given-names>T</given-names></name></person-group><article-title>Therapeutic efficacy and effects of artesunate-amodiaquine and artemether-lumefantrine on malaria-associated anaemia in Nigerian children aged two years and under</article-title><source>Infectious Diseases of Poverty</source><year>2016</year><volume>5</volume><fpage>70</fpage><pub-id pub-id-type="doi">10.1186/s40249-016-0165-2</pub-id><pub-id pub-id-type="pmid">27384596</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gbotosho</surname><given-names>GO</given-names></name><name><surname>Sowunmi</surname><given-names>A</given-names></name><name><surname>Okuboyejo</surname><given-names>TM</given-names></name><name><surname>Happi</surname><given-names>CT</given-names></name><name><surname>Folarin</surname><given-names>OO</given-names></name><name><surname>Michael</surname><given-names>OS</given-names></name><name><surname>Adewoye</surname><given-names>EO</given-names></name></person-group><article-title>Therapeutic efficacy and effects of artemether-lumefantrine and artesunate amodiaquine co-formulated or co-packaged on malaria-associated anemia in children with uncomplicated <italic>Plasmodium falciparum</italic> malaria in southwest Nigeria</article-title><source>Am J Trop Med Hyg</source><year>2011</year><volume>84</volume><fpage>813</fpage><lpage>819</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.2011.10-0582</pub-id><pub-id pub-id-type="pmid">21540395</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sowunmi</surname><given-names>A</given-names></name><name><surname>Gbotosho</surname><given-names>GO</given-names></name><name><surname>Happi</surname><given-names>CT</given-names></name><name><surname>Folarin</surname><given-names>O</given-names></name><name><surname>Okuboyejo</surname><given-names>T</given-names></name><name><surname>Michael</surname><given-names>O</given-names></name><name><surname>Fatunmbi</surname><given-names>B</given-names></name></person-group><article-title>Use of area under the curve to evaluate the effects of antimalarial drugs on malaria-associated anaemia after treatment</article-title><source>Am J Ther</source><year>2011</year><volume>18</volume><fpage>190</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1097/MJT.0b013e3181d169c9</pub-id><pub-id pub-id-type="pmid">20683244</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Rowland</surname><given-names>M</given-names></name><name><surname>Tozer</surname><given-names>TN</given-names></name></person-group><source>Clinical pharmacokinetics: concept and application</source><year>1980</year><publisher-loc>Philadelphia</publisher-loc><publisher-name>PA Lea and Ferbiger</publisher-name></element-citation></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="other">Bain BJ, Bates I. Basic haematological techniques. In: Lewis SM, Bain BJ, Bates I, editors. Practical Haematology. 9th ed. Edinburgh: Churchill Living stone 2001; pg. 19&#x02013;46.</mixed-citation></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="other">Epi Info Version 6. A Word Processing Data Base and Statistics Program for Public Health on IBM-compatible Microcomputers. Centers for Disease Control and Prevention, Atlanta, GA; 1994.</mixed-citation></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="other">SPSS for Windows Release 20.0 (standard version). SPSS Inc., Chicago IL; 2011.</mixed-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bland</surname><given-names>JM</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name></person-group><article-title>Statistical methods for assessing agreement between two methods of clinical measurement</article-title><source>Lancet</source><year>1986</year><volume>1</volume><fpage>307</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(86)90837-8</pub-id><pub-id pub-id-type="pmid">2868172</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sowunmi</surname><given-names>A</given-names></name><name><surname>Akano</surname><given-names>K</given-names></name><name><surname>Ayede</surname><given-names>AI</given-names></name><name><surname>Adewoye</surname><given-names>EO</given-names></name><name><surname>Ntadom</surname><given-names>G</given-names></name><name><surname>Fatunmbi</surname><given-names>B</given-names></name><name><surname>Gbotosho</surname><given-names>GO</given-names></name><name><surname>Folarin</surname><given-names>OA</given-names></name><name><surname>Happi</surname><given-names>CT</given-names></name></person-group><article-title>Early rising asexual parasitaemia in Nigerian children following a first dose of artemisinin-based combination treatments of falciparum malaria</article-title><source>BMC Infect Dis</source><year>2017</year><volume>17</volume><fpage>110</fpage><pub-id pub-id-type="doi">10.1186/s12879-016-2173-z</pub-id><pub-id pub-id-type="pmid">28143417</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sowunmi</surname><given-names>A</given-names></name><name><surname>Akano</surname><given-names>K</given-names></name><name><surname>Ntadom</surname><given-names>G</given-names></name><name><surname>Ayede</surname><given-names>AI</given-names></name><name><surname>Ibironke</surname><given-names>FO</given-names></name><name><surname>Aderoyeje</surname><given-names>T</given-names></name><name><surname>Adewoye</surname><given-names>EO</given-names></name><name><surname>Fatunmbi</surname><given-names>B</given-names></name><name><surname>Oguche</surname><given-names>S</given-names></name><name><surname>Okafor</surname><given-names>HU</given-names></name><name><surname>Watila</surname><given-names>I</given-names></name><name><surname>Meremikwu</surname><given-names>M</given-names></name><name><surname>Agomo</surname><given-names>P</given-names></name><name><surname>Ogala</surname><given-names>W</given-names></name><name><surname>Agomo</surname><given-names>C</given-names></name><name><surname>Folarin</surname><given-names>OA</given-names></name><name><surname>Gbotosho</surname><given-names>GO</given-names></name><name><surname>Happi</surname><given-names>CT</given-names></name></person-group><article-title>Therapeutic efficacy and effects of artemisinin-based combination treatments on uncomplicated <italic>Plasmodium falciparum</italic> malaria-associated anaemia in Nigerian children during seven years of adoption as first-line treatments</article-title><source>Infectious Diseases of Poverty</source><year>2017</year><volume>6</volume><fpage>36</fpage><pub-id pub-id-type="doi">10.1186/s40249-016-0217-7</pub-id><pub-id pub-id-type="pmid">28173853</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sowunmi</surname><given-names>A</given-names></name><name><surname>Balogun</surname><given-names>T</given-names></name><name><surname>Gbotosho</surname><given-names>GO</given-names></name><name><surname>Happi</surname><given-names>CT</given-names></name><name><surname>Adedeji</surname><given-names>AA</given-names></name><name><surname>Fehintola</surname><given-names>FA</given-names></name></person-group><article-title>Activities of amodiaquine, artesunate, and artesunate-amodiaquine against asexual and sexual stage parasites in falciparum malaria in children</article-title><source>Antimicrob Agents Chemother</source><year>2007</year><volume>51</volume><fpage>1694</fpage><lpage>1699</lpage><pub-id pub-id-type="doi">10.1128/AAC.00077-07</pub-id><pub-id pub-id-type="pmid">17325222</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="other">Sowunmi A, Okuboyejo TM, Gbotosho GO, Happi CT. Early changes in <italic>Plasmodium falciparum</italic> asexual and sexual populations in children with acute infections following treatment with artemisinin-based combination drugs. Malaria Chemotherapy Control and Elimination. 2012;1 doi:10.4303/mcce/235498.</mixed-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robert</surname><given-names>V</given-names></name><name><surname>Read</surname><given-names>AF</given-names></name><name><surname>Essong</surname><given-names>J</given-names></name><name><surname>Tchuinkam</surname><given-names>T</given-names></name><name><surname>Mulder</surname><given-names>B</given-names></name><name><surname>Verhave</surname><given-names>JP</given-names></name><name><surname>Carnevale</surname><given-names>P</given-names></name></person-group><article-title>Effects of gametocyte sex ratio on infectivity of <italic>Plasmodium falciparum</italic> to <italic>Anopheles gambiae</italic></article-title><source>Trans R Soc Trop Med Hyg</source><year>1996</year><volume>90</volume><fpage>621</fpage><lpage>624</lpage><pub-id pub-id-type="doi">10.1016/S0035-9203(96)90408-3</pub-id><pub-id pub-id-type="pmid">9015496</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sowunmi</surname><given-names>A</given-names></name><name><surname>Akano</surname><given-names>K</given-names></name><name><surname>Ntadom</surname><given-names>G</given-names></name><name><surname>Ayede</surname><given-names>A</given-names></name><name><surname>Oguche</surname><given-names>S</given-names></name><name><surname>Agomo</surname><given-names>C</given-names></name><name><surname>Okafor</surname><given-names>H</given-names></name><name><surname>Watila</surname><given-names>I</given-names></name><name><surname>Meremikwu</surname><given-names>M</given-names></name><name><surname>Ogala</surname><given-names>W</given-names></name><name><surname>Agomo</surname><given-names>P</given-names></name><name><surname>Adewoye</surname><given-names>E</given-names></name><name><surname>Fatunmbi</surname><given-names>B</given-names></name><name><surname>Aderoyeje</surname><given-names>T</given-names></name><name><surname>Happi</surname><given-names>C</given-names></name><name><surname>Gbotosho</surname><given-names>G</given-names></name><name><surname>Folarin</surname><given-names>O</given-names></name></person-group><article-title>Anaemia following artemisinin-based combination treatments of uncomplicated <italic>Plasmodium falciparum</italic> malaria in children: temporal patterns of haematocrit and the use of uncomplicated hyperparasitaemia as a model for evaluating late-appearing anaemia</article-title><source>Chemotherapy</source><year>2017</year><volume>62</volume><fpage>231</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1159/000449366</pub-id><pub-id pub-id-type="pmid">28448988</pub-id></element-citation></ref></ref-list></back></article>